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Epigenetics involves a variety of biochemical modifications occurring on chromatin 
that are able to regulate and fine-tune genetic activities without altering the underlying 
DNA sequence. So far, four types of epigenetic modulation have been extensively studied: 
DNA methylation, histone post-translational modificat on, non-coding RNA, and nuclear 
organization. A fast-growing body of evidence suggests that epigenetic mechanism plays 
a fundamental role in physiology and pathology. Of the elucidated epigenetic processes, 
DNA methylation is the one under intense research due to its direct impact on gene ex-
pression, which dynamically bridges the microscale genotype and macroscale phenotype. 
However, to date our understanding of DNA methylation has primarily come from en-
semble and end-point measurements using a population of cells or bulky samples. Unlike 
genetic aberrations (e.g., amplification, deletion, translocation, and mutation) that are rare 
to occur and resistant to reverse, events relating to epigenetic modifications take place in 
a time- and context-dependent manner, thus necessitating nanoscale tools to dissect epi-
genetic dynamics at a finer spatiotemporal resolutin. In my Ph.D. work, a group of ad-
vanced single-molecule fluorescence tools, in addition to methodologies in bioengineer-
ing, nanotechnology, molecular biology, and bioinformatics, is implemented to approach
xx 
 
the DNA methylation-related activities. Furthermore, part of my research aims to trans-
late the new discoveries from single-cell experiments to biomedical applications. Another 
focus of my dissertation is on effective manipulation of DNA methylation by novel tech-
niques including nanomaterials and optogenetics. Taken together, these efforts lay the 
groundwork for better understanding of DNA methylation and provide ample avenues for 
improving epigenetic therapies. 
After the introduction chapter, the second and third chapters of my dissertation cen-
ter on elucidating the behavior of MBD3 protein within a single living cell, in order to 
infer the real-time dynamics of DNA methylation. Taking use of fluorescence correlation 
spectroscopy (FCS), fluorescence lifetime imaging (FLIM), Förster resonance energy 
transfer (FRET), and photon counting histogram (PCH), the in situ binding preference, 
dissociation kinetics, and stoichiometric transition f MBD3 were probed with unprece-
dented precision. Due to the substitution of two amino acids in its DNA-binding motif, 
MBD3 has evolved to differ from other MBD homologues in physicochemical properties 
as well as in biological functions. Consequently, its altered binding affinity and specifici-
ty with DNA methylation lead to unique molecular behaviors that can be sensed by sin-
gle-molecule techniques. In this line of research, 1) the intracellular diffusion of MBD3 
was explored to monitor active DNA demethylation and 2) the cell cycle-dependent ac-
tivity of MBD3 was characterized. In these attempts my study establishes the dissociation 
of MBD3-DNA as a marking event in active DNA methylation, which might be involved 
in early oncogenesis. Moreover, the role of MBD3 in the DNA maintenance methylation 




Considering its importance in DNA methylation, MBD3 was proposed to participate 
in brain cancer because the central nervous system possesses abundant DNA methylation 
marks and active methyl metabolism. Hence in the fourth chapter of my dissertation the 
regulatory landscape and clinical implication of MBD3 in human malignant glioma is 
studied. Utilizing whole-genome transcriptome microar ay, the MBD3-mediated epige-
netic regulation in glioma was profiled. The data uncover that MBD3 stands in the midst 
of an exquisite anti-glioma network via influencing a large number of transmembrane 
proteins and nuclear factors. By analyzing the differentially expressed genes upon deple-
tion of MBD3, the MHC class II molecules were identified to be a group of downstream 
effectors activated by MBD3, which provides important insight into the anti-glioma im-
munity. Furthermore, MBD3 functions to impact a wide range of non-coding RNAs in-
cluding the oncogenic miR-17-92 cluster whose dysfunction could lead to an aggressive 
glioma proliferation and metastasis. From a pilot clini al study, the expression level of 
MBD3 was found to positively correlate with the patien  prognosis and thus could be ex-
plored as a novel epigenetic biomarker.   
Reactivation of tumor supper genes using DNA demethylating agents has proven to 
be effective in treating hematopoietic malignancies, but efficient delivery of these drugs 
into solid tumors is a challenging task. In the fifth chapter a polymeric nano-vector com-
prising PLGA and PEG is developed to improve the solubility, bioavailability, and thera-
peutic potency of the FDA-approved DNA demethylating agents – AZA and DAC. With 
equimolar drug content, the nano-conjugated AZA showed better anti-proliferative effect 
than free drug in treating xenografted breast cancer. This formulation can also be used to 
deliver a safe dosage of DAC for sensitizing the alkyl tion-resistant glioblastoma cells to 
xxii 
 
temozolomide. Moreover, the improved cell uptake and drug release was characterized 
by single-molecule tools. The results demonstrate that PLGA-PEG nano-micelles could 
rapidly enrich in cancer cells and resist to efflux. Notably, the pH-dependent hydrolysis 
of PLGA enables a targeted drug release in acidic cancer cells featuring overactive gly-
colysis. Hence, this line of research describes a novel strategy to enhance epigenetic ther-
apy and provides a cost-effective option for future pharmaceutical applications. 
The sixth chapter of my dissertation presents a light-controllable technique for loci-
specific epigenome editing. The optogenetic proteins CRY2-CIB and PHYB-PIF are pho-
tosensitive pairs whose associations can be induced by blue and red light, respectively. 
Under proper illumination, CRY2 or PHYB is rapidly photoactivated to couple with CIB 
or PIF, and their optogenetic associations are reversibl  in the absence of the triggering 
light. The first half of this chapter elucidates the feasibility of using single-molecule fluo-
rescence tools to characterize real-time optogenetic binding kinetics. In the second half, a 
pair of DNMT3A-CRY2-mCherry and TRF1-CIB1-EGFP fusion proteins was construct-
ed to achieve selective de novo DNA methylation at subtelomeric CpGs. By varying the 
illumination conditions, the subtelomeric methylation can be incrementally manipulated. 
These optogenetic modules provide a powerful way to study DNA methylation and can 
be conveniently adapted for multiplexing epigenome editing and in vivo applications. 
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CHAPTER 1. INTRODUCTION 
1.1 Epigenetics and DNA Methylation 
According to the definition by the NIH “Roadmap Epigenomics Project,” “Epignet-
ics is an emerging frontier of science that involves the study of changes in the regulation 
of gene activity and expression that are not dependent on gene sequence.” Epigenetic 
modifications, through modulating the physicochemical properties of chromatin, dynami-
cally switch on and off the transcription of relevant genes. One of the longest studied epi-
genetic mechanisms is DNA methylation, i.e., the transfer of a methyl group from S-
adenosylmethionine (SAM) to 5-carbon of the pyrimidine ring in cytosine (Figure 1.1). 
DNA methylation is intimately involved in life and diseases, and the DNA methylome of 
a particular cell or organism can be inherited over g nerations. Therefore, understanding 
of DNA methylation constitutes a cornerstone for modern biology and medicine. 
 
1.1.1 Overview 
For a typical human cell, 3 billion base pairs (bp) of DNA are compacted in its nu-
cleus, which however only encode approximately 21,000 genes. This limited repertoire of 
genes is shared by numerous differentiated cells and expressed in a precisely controlled 
manner during the lifespan of every person. For a long period in history, it has baffled 
scientists why monozygotic twins could have distinct personalities and susceptibilities
2 
 
to certain diseases even though they boasted the identical genomic information. Genetics 
alone is far from sufficient to explain the biological diversity and phenotypic variations 
thereto. In 1940s, C.H. Waddington first coined the term “epigenotype” to describe the 
causal interactions between the genotype and phenotype during development.1 However, 
it was vastly unknown on what mechanism bridged a fixed set of genetic materials to the 
developmental divergence among somatic cells in a metazoan organism. First discovered 
by T.B. Johnson and R.D. Coghill in 1925,2 the presence of 5-methylcytosine (5mC) was 
later proposed to inactivate one X chromosome in femal  genome and in 1970s 5mC was 
established to be a negative regulator for gene expression.3, 4 Since then, DNA methyla-
tion and other epigenetic modifications have filled the gap to explain the time- and con-
text-dependent gene expression in a single cell. Over the past decades, researches have 
accumulated to reach the conclusion that DNA methyla ion is indispensable for virtually 
all biological processes.  
In mammalian cells, the enzymatic reaction of DNA methylation preferably occurs at 
a CpG dinucleotide that is not uniformly distributed over the genome. A considerable 
portion of CpGs concentrate in short clusters and stretches called CpG islands [CGI, a 
500-2,000 bp region having at least 50% of CG content and 60% of an observed-to-
expected CpG ratio, i.e., number of CpGs × length of sequence/(number of C × number 
of G)] near or within the transcription start site of genes (e.g., promoters). Although 70%-
80% of scattered CpGs are methylated, most CGIs in promoters are devoid of DNA 
methylation to keep the genes poised for activation. Once heavily methylated under a dis-
eased condition, the promoter region would be condensed by a series of repressor factors 




Figure 1.1 Diagram of DNA methylation. A methyl group is transferred from SAM to 
cytosine by DNMT enzyme to repress a gene. 
 
In the epigenetic network, DNA methylation is not an isolated modulator but often-
times connect a wide range of partners to achieve transcriptional inhibition. For instance, 
5mC site could recruit methyl-CpG-binding domain protein 2 (MBD2) and its associated 
Mi-2/NuRD complex containing histone deacetylases (HDACs) to temporarily turn down 
a gene.5 In comparison, 5mC occupied by methyl-CpG-binding protein 2 (MeCP2) would 
attract the histone H3 lysine 9 (H3K9) methyltransferase SETDB1 and heterochromatin 
protein 1 (HP1).6 In this scenario, DNA methylation acts in cohort with histone modifica-





1.1.2 DNA Methylation in Life and Diseases 
For a healthy cell where most of its CGIs in promoters are unmethylated, the CpGs 
in other regions such as gene bodies and intergenic r petitive elements are heavily meth-
ylated to maintain the chromosomal integrity and stability. In the embryogenesis and de-
velopment of a diploid organism, DNA methylation also plays a crucial role. All human 
genes have two alleles with one from the maternal germ cell and the other from the pater-
nal source. Genomic imprinting is an epigenetic process by which some genes are ex-
pressed in a parent-of-origin-specific manner. If only the allele from the mother needs to 
be transcribed, the other one from the farther has to be imprinted, i.e., silenced by DNA 
methylation. Under a similar circumstance, the femal  somatic cells have two X chromo-
somes but only one copy is transcriptionally active whereas the other one is often epige-
netically inactivated. This X-chromosome inactivation is controlled by an exquisite 
mechanism that primarily depends on the DNA methylaion mediated heterochromatin 
formation. Another critical process involving DNA methylation lies in tissue differentia-
tion and lineage fidelity. For a mature tissue or organ to carry out its normal function, not 
all the genes in genome are required. Differentiated from a pluripotent stem cell to a par-
ticular cell type, a large number of unneeded genes ar  switched off by DNA methylation 
and this epigenetic memory would be faithfully passed down to keep the lineage identity. 
Despite that DNA methylation at the gene promoter directly suppress that gene, intragen-
ic DNA methylation is also able to fine-tune the activity of RNA polymerase and the al-
ternative splicing of mRNAs.7, 8  
Due to its functional versatility and importance, DNA methylation is implicated in a 
myriad of pathological conditions. Mistakes in genomic imprinting have pleiotropic con-
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sequences such as placental deficiencies, fetal undergrowth or overgrowth, increased risk 
of childhood cancers, neurological defects and developmental retardation. The Angelman 
(AS) and Prader-Willi (PWS) syndromes are two distinct, reciprocally imprinted disor-
ders that share the same chromosomal location. Lossor inactivation of at least one 
15q11-13 gene occurs in AS and PWS, with maternal deficiencies giving rise to AS and 
paternal defects causing PWS. Thus for the genes involved in AS and PWS, both of their 
alleles are not functional because one is silenced by imprinting and the other one is mu-
tated. Other common imprinting disorders include: Beckwith-Wiedemann syndrome 
(11p15), Russell-Silver syndrome (11p15), Albright’s hereditary osteodystrophy (20q13), 
and NOEY2 dysfunction (1p31).9 
Recently, in a plethora of studies aberrant DNA methylation has been defined as a 
driving force for oncogenesis. The best-characterized epigenetic events in relation to can-
cer are: 1) global DNA hypomethylation and 2) intens  hypermethylation at the promot-
ers of certain tumor suppressor genes.10 The epigenome of a cancer cell could be depleted 
by 20%-60% of its DNA methylation, mostly at coding regions, enhancers, introns, and 
repetitive sequences. In the cancerous DNA demethylation, one destructive effect arises 
via activation of the endogenous retrovirus and transposable elements present in mamma-
lian genomes, which in turn potently compromise the expression of growth regulatory 
genes, foster genome-wide mutations, and enforce fatal chromosomal recombinations. De 
novo methylation at the promoter region of tumor suppressor genes is another critical step 
facilitating cancer initiation. Although the majority of promoters CGIs are free of DNA 
methylation, an anomalous gain-of-methylation for a key tumor suppressor gene could 
unduly release the precancerous cells from the restrictions on proliferation, metabolism, 
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adherence, and metastasis. Notably, the pattern of promoter hypermethylation in some 
genes is highly tissue-specific and thus can be explored as novel biomarkers. For example, 
upon DNA hypermethylation, the deregulation of BRCA1 is a hallmark of breast and 
ovarian tumors, and the repression of hMLH1 predominantly occurs in endometrial, colo-
rectal, and gastric neoplasm.11 In contrast, hypermethylation of the MGMT gene can 
bring about a prognostic benefit for glioma patients who receive the standard alkylating 
chemotherapy (e.g., temozolomide) because inactivation of MGMT alleviates the intrin-
sic activity of reversing the therapeutic guanine alkyl tion. 
 
1.1.3 DNA Methylation-Related Enzymes 
Conserved along cell division, modified during cell differentiation, and transgressed 
in cell transformation, the patterns of genome-wide DNA methylation actively dictate cell 
fate and are under a rigorous control by methyltransferases and demethylases. Thus the 
DNA methylation homeostasis is stringent on a delicate balance between these two forces 
of enzymes and their co-factors.  
The addition of a methyl mark to cytosine is mainly catalyzed by DNA methyltrans-
ferases (DNMTs) in human cells, and to date three genuine DNMTs have been biochemi-
cally characterized with the exception that DNMT2 was later found to be a RNA methyl-
transferase.12 The catalytic domain of DNMTs is highly conserved, featuring a ~400 ami-
no acids sequence containing motifs I-X in the C-terminus.13 The N-terminal regulatory 
domain distinguishes DNMT1 from DNMT3A/B: a proliferating cell nuclear antigen 
(PCNA)-binding domain (PBD), a pericentric heterochromatin-targeting sequence (TS), a 
CXXC zinc finger motif, and two bromo adjacent homology (BAH) domains are con-
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tained in DNMT1; in comparison, the N-terminal domain of DNMT3A and DNMT3B is 
composed of a conserved Pro-Trp-Trp-Pro PWWP domain and a plant homeodomain 
(PHD, also known as ADD, i.e., ATRX-DNMT3-DNMT3L) in their N-terminus (Figure 
1.2A). DNMT1 was discovered in 1988 and DNMT3A/B were discovered ten years lat-
er.14, 15 In the early years, based on their binding preference for hemi-methylated or un-
methylated DNA, these DNMTs were arbitrarily categorized as maintenance methyltrans-
ferase (DNMT1) and e novo methyltransferase (DNMT3). DNMT1 is the most abunda t 
DNMT throughout the life cycle of a differentiated cell whereas DNMT3 largely enriches 
in early development. DNMT1 starts to peak its exprssion in S-phase and possesses a 
substrate preference for hemi-methylated DNA at replication loci.16 During the estab-
lishment of tissue-specific methylomes from an epignetically naive stem cell, DNMT3A 
and DNMT3B are responsible for adding numerous de novo methylation marks to those 
imprinted genes, satellite sequences, long and short interspersed nuclear elements 
(LINEs/SINEs), and heterochromatin.17 However, in recent years studies have shown that 
actually DNMT1 and DNMT3 are not mutually independet but act in concert for the 
methylation homeostasis.18 DNMT3 can support DNMT1 in the maintenance methylation 
of repetitive elements while overexpression of DNMT1 would result in a marked gain of 
de novo methylation.19, 20     
In the production of germ cells, the DNA methylation landscape in the gametes, es-
pecially the paternal copy, undergoes a rapid and massive demethylation. However, the 
first active DNA demethylase in human was not found til 2009.21 Before that, the con-
ventional view in the removal of DNA methylation inclined to: 1) DNA demethylation 
needs to be achieved via a passive dilution (.e., the hemi-methylated sites are stopped to 
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become fully methylated after DNA replication) or 2) the methylated cytosine should ex-
perience deamination to become thymine and then be replaced by a new cytosine through 
the base excision repair (BER), yet both of which were deemed as utterly inefficient pro-
cesses. Since the recent discovery of the ten-eleven-translocation (TET) family protein-
catalyzed conversion of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine 
(5fC), and 5-carboxylcytosine (5caC), the full picture of DNA demethylation has come to 
our sight: the oxidation of 5mC essentially facilitates the passive and active demethyla-
tion processes. The existence of 5hmC at hemi-methylated sites (i.e., 5’-5mC-G-3’:3’-G-
5hmC-5’ pairs) can remarkably accelerate the passive demethylation while 5fC and 5caC 
are better substrates to be processed by thymine DNA glycosylase (TDG) in BER.22 TET 
family proteins (TET1-3) are a group of Fe(II)/α-ketoglutarate (α-KG)-dependent oxy-
genases and harbor a double-stranded β-helix (DBSH) core motif where high-valet Fe(IV) 
is generated to oxidize the methyl group on cytosine. TET1 and TET3 also contain a 
CXXC domain in their N-terminus to facilitate bindig with CG-rich sequences (Figure 
1.2B). TET3 is predominantly enriched in zygotes and responsible for the active demeth-
ylation of the paternal epigenome while TET1 and TET2 are more expressed in primordi-
al germ cells. In some tissues (e.g., brain, heart, lung, liver, and kidney) TET proteins are 





Figure 1.2 Schematic illustration of human methyltransferases and demethylases. 
 
Aberrant expression or mutations of DNMTs and TETs are extensively implicated in 
various diseases, particularly in hematopoietic malign ncies. The pathological transloca-
tion of mixed lineage leukemia protein (MLL)-TET1 [t(10;11)(q22;q23)] is a common 
event in acute myeloid leukemia (AML).25 TET2 is frequently mutated in lymphoma, 
myelodysplastic syndrome (MDS), myelofibrosis, and different types of leukemia.24 Mu-
tations in DNMT3A are usually correlated with poor prognosis for patients having AML 
or MDS.26, 27 The biallelic DNMT3B mutation is the main cause for the rare “immunode-
ficiency, centromeric region instability, and facial anomalies syndrome” (ICF).28 In addi-
tion, abnormal DNA methylation induced by dysfunctional DNMTs or TETs could sub-
stantially promote solid tumor initiation and progression. 
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1.1.4 DNA Methylation-Binding Proteins 
Besides the methylation-editing enzymes, methylated cytosine can also be recog-
nized by a group of reader proteins including Kaiso family proteins, MBD family pro-
teins, and the SET- and Ring finger-associated (SRA) domain proteins (Figure 1.3). 
These proteins either function as a structural component of chromatin or serve as a coor-
dinator to connect other factors. Kaiso and Kaiso-lke proteins interact with DNA meth-
ylation through three Kruppel-like C2H2 zinc finger motifs but they require two consecu-
tive mCpGs for an efficient binding.29, 30 In cooperation with HDACs and chromatin-
remodeling factors, Kaiso turns out to be a strong transcription repressor. The first MBD 
protein MeCP2 was discovered in 1992,31 followed by the discovery of the other MBD 
members in the next several years. Till today at lest ten MBD-containing proteins have 
been identified in human being. The core DNA-binding motif of MBD proteins contains 
about 70 residues folding into an α/β sandwich structure that is embedded into the major 
groove of target DNA sites.32 The binding specificity and affinity between MBD and 
DNA methylation is subjected to changes of some key residues such as Val-20, Arg-22, 
Lys-30, Tyr-34, Arg-44, and Ser-45.32-34 For instance, the human MBD2 and MBD3 are 
highly homologous, but MBD3 has a much weaker in vitro binding affinity with 5mC 
owing to the K30H and Y34F substitution.35 Over the past years the SRA domain-
containing protein UHRF1 (also known as NP95 or ICBP90) has drawn considerable at-
tention since the finding that UHRF1 could co-localize with hemi-methylated DNA and 
DNMT1 during the S-phase in cell cycle.36-38 After locating a hemi-methylated CpG site, 
UHRF1 would quickly move in and flip the methylated cytosine out of the double helix, a 
characteristic conformation subsequently recruiting DNMT1 to transfer a methyl group to 
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the unmethylated CpG on the complementary strand. This discovery reveals that UHRF1 
is a vital part in the DNA maintenance methylation. 
 
 
Figure 1.3 Solved structures of major DNA methylation-binding proteins. This figure was 
generated using PyMOL with structural information retrieved from the RCSB PDB data-
base: Kaiso (PDB ID: 4F6N), MBD (PDB ID: 2YK8), SRA (PDB ID: 2ZO1). 
 
As mentioned above, DNA methylation-binding proteins have evolved to gain a di-
versity of functions to interpret the epigenetic code on DNA. To effectively regulate a 
gene, DNA methylation often needs to co-work with oer epigenetic modulators. For 
instance, a number of DNA methylation-binding proteins (e.g., Kaiso, MeCP2, MBD2, 
MBD3, and SRA) directly or indirectly associate with HDACs; MBD1 usually co-exists 
with H3K9 trimethylation and HP1; and both MBD2 and MBD3 are core subunits of the 
nucleosomal remodeling deacetylase complex Mi-2/NuRD.39 Interestingly, under certain 
circumstances some MBD proteins (e.g., MBD2, MBD3, and MBD4) can interact with 
unmethylated DNA or even demethylate their binding sequences.40-42 In this regard, these 
proteins might also be involved in gene activation.    
A multitude of diseases and disorders are linked to DNA methylation-binding pro-
teins. The best-known one is Rett syndrome, a neurod velopment disorder caused by mu-
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tations in MeCP2.43 MBD3 is important for development and deletion of MBD3 in mouse 
model is embryonic lethal.44 Except for MBD2, mutations in all other MBD proteins have 
been identified in autism spectrum disorder.39 In cancers, abnormal expression of one or 
more MBD proteins has been frequently observed, such as overexpression of MeCP2 and 
MBD2 in breast cancer,45 overexpression of MBD2 and MBD4 in brain glioblastoma,46, 
47 up-regulation of MBD1 and down-regulation of MBD2 in prostate cancer,48 and down-
regulation of MBD3 in gastrointestinal and endometrial cancers.49, 50 
 
1.2 Nanoscale Detection and Manipulation of DNA Methylation 
At present our understanding of epigenetic regulation has primarily come from en-
semble, static, and end-point tests utilizing a population of cells or bulky samples, largely 
overlooking the cellular heterogeneity and real-time intermediates. In order to dissect and 
engineer a single cell, achieving a finer experimental scale than that in the conventional 
biological approaches is imperative. Advanced single-molecule fluorescence techniques 
open a unique window for us to inspect epigenetic molecules and events with marvelous 
resolutions. In the meantime, nanobiotechnology provides us tremendous opportunities to 
edit epigenome with unprecedented convenience and accuracy. 
 
1.2.1 Overview 
In eukaryotic cells, the basic unit for epigenetic regulation is nucleosome that con-
tains a histone octamer core wrapped by 147 bp of DNA (Figure 1.4). Epigenetic modifi-
cations function through influencing the intertwined DNA-histone interface to control 
gene transcription. However, the extremely small size of a single nucleosome – approxi-
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mately 11 nm – poses a daunting task to detect or manipulate a specific type of epigenetic 
mark on it.  
 
 
Figure 1.4 Basic unit for epigenetic modifications to occur – a single nucleosome.  
 
Capturing and controlling epigenetic events in single living cells require the spatial 
and temporal resolution of the methodology to meet th  scales of the ongoing cellular and 
molecular activities (Figure 1.5). Yet the intracellular environment is extremely crowded. 
Given a human cell with an average volume of ~1 picoliter, 3 × 109 bp DNA (equivalent 
to 2 meters if fully stretched) is packed in its nucle s whose diameter is merely 10-15 mi-
crons. Even DNA methylation only constitutes ~1% of the human genome, which could 
generate a fairly high in situ density of 5mC at particular regions such as satellite DNA 
repeats and heterochromatin sites. To overcome the bottleneck of microscopic observa-
tion, nanoscale imaging and molecular engineering are becoming increasingly important. 
On a different note, the genome-wide content of DNA methylation is dynamically fluctu-
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ating along with different cell behaviors, posing another layer of complexity for single-
cell studies.  
 
 
Figure 1.5 Spatiotemporal scales required for single-cell and single-molecule studies. 
 
1.2.2 Single-Molecule Fluorescence Techniques 
About 340 years have passed since Robert Hooke and Antonie van Leeuwenhoek 
popularized the modern microscopy. The 20th century has embraced an exciting number 
of breakthroughs that rendered optical microscope an irreplaceable part in life science 
research. The invention of fluorescence microscope in 1910s has spurred a revolutionary 
leap, after which fluorescent labeling has quickly become the norm for observing micro-
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organisms and subcellular structures. Derived from the principle of fluorescence, the fur-
ther developments of confocal microscopy (1960s), fluorescence fluctuation microscopy 
(1970s), total internal reflection fluorescence micros opy (1980s), multi-photon micros-
copy (1990s), light-sheet fluorescence microscopy (1990s), and super-resolution micros-
copy (2000s) have been enormously advancing the spatiotemporal limits of optical dis-
section. The capability of single-molecule fluorescn e techniques to provide in situ, re-
al-time information of intracellular dynamics is anu paralleled advantage. In this thesis, 
a toolset of ultrafast pulsed lasers and single-photon avalanche diode (SPAD) detectors 
are integrated into a scanning confocal time-resolved microscope system (PicoQuant) for 
probing the DNA methylation-related activities. The mainly used techniques are depicted 





Figure 1.6 Function modules in a single-molecule fluorescence platform. The system is 
based on an inverted confocal scanning microscope. Ultrafast pulsed lasers and SPAD 
detectors are implemented to realize time-correlated single-photon counting. In the con-
focal detection volume, the recorded fluorescence fluctuation can be used for FCS and 
PCH, and the photon decay pattern can be interpreted in FLIM.   
 
Fluorescence correlation spectroscopy (FCS). First developed by Douglas Madge, Elliot 
Elson, and W.W. Webb in 1972, FCS takes use of the spontaneous fluorescence fluctua-
tion (at a microsecond resolution) due to the molecular diffusion in-and-out a femtoliter-
level volume to biophysically infer the concentration, diffusion rate, hydrodynamic size, 
and interaction kinetics of the fluorescent targets.51, 52 In FCS analysis, an autocorrelation 
function is extracted from the fluorescence fluctuation trace which describes the similari-
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where F  is the average fluorescence intensity over time (t), and ( ) ( ) ( )F t F t F tδ = − . 
For 3D free diffusion, the autocorrelation function can be correlated to single-molecule 
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where N  is the average number of molecules, if  is the fraction of species i, κ  is the 
spatial dimension of the detection volume (the ratio of radial 0w  to axial 0z  radii), and 
Diτ  is the characteristic diffusion time (the average time for one molecule dwelling in the 
detection volume). The concentration of molecules can be calculated as: / effC N V= , 
where effV  is the effective detection volume: 
3/2 2
0 0effV w zπ= . From Dτ  the diffusion coef-
ficient (D) of molecules can be calculated as: 20 / 4 DD w τ= . The hydrodynamic size (R) 






where k  is the Boltzmann’s constant and η  is the environmental viscosity. For a con-
strained diffusion condition such as 2D diffusion and anomalous restricted diffusion, dif-
ferent fitting models should be opted accordingly.  
Photon counting histogram (PCH). The sensitivity of FCS to distinguish different mole-
cules heavily relies on molecular size, which requires a minimum of 1.6-fold change in 
hydrodynamic size or 4.1-fold change in molecular weight to separate two species.53 The 
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invention of PCH method greatly enriches the single-molecule toolbox with another fluo-
rescent characteristic – molecular brightness (ε), which is especially useful to reflect the 
stoichiometry of fluorophores having oligomeric status.54, 55 Collected as the average 
number of photons emitted from per molecule per sampling time, single-molecule bright-
ness is physically defined by: 
0
N
wI Tε βη=  
where T is the integration time increment, wη  is the detection efficiency, I0 is the maxi-
mum excitation at the center of detection volume, N is 1 for single-photon system, β is 
the excitation probability. The weight averaged ε  is independent of the ensemble con-
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where εi is the brightness of species i, fi is its fractional intensity, and σ
2 is the detection 
variance. The gamma factor (γ) is an excitation-dependent value and is 0.3536 for single-
photon confocal system. 
Fluorescence lifetime imaging microscopy (FLIM). Fluorescence lifetime (τ, a different 
parameter from the time lag in autocorrelation function) is defined as the average time 
one fluorochrome stays at the excited state before returning to the ground state by emit-





where Γ is the emission rate and knr the non-radiative decay rate, both of which are sub-
jected to physicochemical influences. Fluorescence lifetime is independent of molecule 
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concentration and excitation intensity so that can be used a robust measure to sense con-
formational changes, associations, and environmental factors. In the time-domain FLIM, 
fluorescence lifetime is derived from the time-correlated single-photon counting (TCSPC) 
histogram that records the arrival time of photons u der pulsed excitation (Figure 1.7). 
 
 
Figure 1.7 Schematic of time-domain fluorescence lifetime measurement. After a pulsed 
excitation, the arrival time of each collected photon is compiled to a TCSPC histogram. 
Fluorescence lifetime herein is determined as the decay time for the highest F0 to become 
F0/e. 
 
Förster resonance energy transfer (FRET). Discovered by Theodor Förster in 1946, 
FRET is a physical process of non-radiative energy t ansfer between two fluorochromes 
with proper spectral overlap and dipole-dipole orientation (Figure 1.8). The FRET effi-
ciency (E) greatly depends on the distance (r) between the donor and acceptor with an 











FRET mainly manifests within an inter-dipole distance of 1-6 nm and therefore can 
serve as a biophysical “ruler” to scrutinize molecuar interactions. When acceptor mole-
cules are nearby, a reduction in the fluorescence lifetime of donor molecules indicates the 
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Figure 1.8 FRET and FLIM-FRET. Non-radiative energy transfer would occur when the 
donor and acceptor are closer than 10 nm. The FRET efficiency depends on the distance 
between the dipole moments of fluorophores. FRET leads to a reduction in the fluores-
cence lifetime of donor and can be visualized in FLIM images. 
 
1.2.3 Epigenetic Therapy 
Epigenetic pathology has the potential to reshape cellular functions and appreciably 
foster an oncogenic transformation. As mentioned above, epigenetic silencing of tumor 
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suppressor genes is one of the driving events in cancer progression and drug resistance. 
Fortunately, epigenetic errors in cancer, unlike genetic aberrations, can be reversed by 
proper agents with relative ease and less side effects because epigenetic modifications do 
not alter the DNA sequence.56, 57 This property makes epigenetic therapy a promising in-
tervention strategy. DNA methylation and histone deacetylation are the two major mech-
anisms to compress chromatin and inhibit gene expression. Therefore inhibitors targeting 
DNMTs and HDACs have been designed and synthesized as a new line of chemotherapy. 
So far, five epigenetic drugs have been approved by US Food and Drug Administration 
(FDA): 5-azacytidine (AZA, 2004) and 5-aza-2’-deoxycytidine (DAC, 2006) for treating 
MDS; vorinostat (2006) and romidepsin (2009) for trea ing cutaneous T cell lymphoma; 
and panobinostat (2015) for treating multiple myeloma, while more compounds are under 
clinical trials or preclinical investigations.57, 58  
AZA and DAC are cytidine analogues with their 5-carbon replaced by a nitrogen at-
om so that cannot be methylated by DNMTs anymore. Upon uptake by cells, these cyti-
dine analogues are triphosphorylated and integrated in o newly synthesized DNA strands 
during the S-phase. After several rounds of cell division, the covalent entrapping and 
subsequent degradation of DNMT1 at the drug incorporation sites would significantly 
deplete the endogenous methylation reservoir, which achieves a therapeutic effect by re-
activating a group of tumor suppressor genes such as p16, RB, PTEN, and hMLH1.58-61 
As an alternative, a handful of non-nucleoside molecules are developed to directly target 
the catalytic domain of DNMTs or HDACs by which the d regulated genes can be re-
stored.62, 63  
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Besides being applied separately, epigenetic therapies are more often used in combi-
nation with other chemo-drugs to achieve a prognostic improvement. To name a few, 
AZA could potently sensitize prostate cancer to decetaxel and cisplatin;64 vorinostat and 
paclitaxel together elicit a much stronger anti-ovarian cancer activity;65 both DNMT and 
HDAC inhibitors are effective in sensitizing the tamoxifen-resistant breast cancer to 
hormone therapies.66, 67 Another strategy is to look for synergistic effects from combining 
DNMT and HDAC inhibitors and utilizing their reciprocal modulation on gene activa-
tion.68, 69 One thing worth mentioning, when employing epigenetic treatments, is that they 
would not only reactivate tumor suppressor genes but also boost the expression of cancer-
specific antigens. It thus holds another promise for the incorporation of epigenetic sensi-
tization to the current booming immunotherapy.70 
 
1.2.4 Epigenome Editing 
In order to fully understand the functional implicat on of an epigenetic mark, the ca-
pability of artificially adding or removing such modification in living organisms is an 
emerging challenge. From another perspective, searching for tools that can epigenetically 
regulate genetic activity without altering the coding sequence is becoming a pressing de-
mand for biotechnology. Hence, epigenome editing has been quickly arising as a hot top-
ic in basic research and engineering regime. The first generation of epigenome editing 
derived from conventional techniques such as small interfering RNA (siRNA) or targeted 
mutation to systematically disable an epigenetic enzyme, then depleting a relevant modi-
fication and its regulatory impact. In this way, the majority of epigenetic enzymes and 
factors have been characterized regarding their influe ces on epigenome and phenotypic 
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traits in a variety of model organisms. However, strategic knockout or overexpression of 
an epigenetic protein at the global level cannot adequately address the query on epigenet-
ic control over a specific gene of interest and someti es would even give rise to severe 
side effects since some epigenetic molecules are indispensable for survival. The past dec-
ade has witnessed the soaring popularity of genome engineering enabled by the discovery 
of novel DNA-targeting modules, including zinc finger nucleases (ZFNs),71 transcription 
activator-like effector nuclease (TALENs),72 and clustered regulatory interspaced short 
palindromic repeats and its associated  bacteria endonuclease 9 (CRISPR/Cas9).73 With 
continuing improvements on and implementation of these programmable DNA sequence-
recognition proteins, the next generation of loci-specific epigenome editing has been de-
vised.  
Rather than by introducing DNA breaks, loci-specific epigenome editing is realized 
by replacing the nuclease component in ZFNs, TALENs, or CRISPR/Cas9 with an epige-
netic effector to confer the desired modification onto the targeted sequence (e.g., connect-
ing a deactivated CRISPR/Cas9 to a favorable epigenetic enzyme74, 75) (Figure 1.9). In 
design, an epigenome editing module should comprise two functional domains: a target-
ing domain and an effector domain, between which a linker sequence can be inserted ac-
cording to the covering length.76 The targeting specificity and effectiveness can be evalu-
ated with affinity-based assays such as MeDIP. The prominent advantages for epigenome 
editing over genome editing include: first, the outcome from epigenome editing is more 
predictable whereas the homologues recombination and no -homologous end-joining in-
duced by genome-editing nucleases may lead to entirely different phenotypes; second, the 
extent of gene expression by epigenome editing can be fine-tuned in contrast to a dichot-
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omous on/off effect by genome editing. Substantive att mpts have been invested and they 
successfully laid the foundation on how to harness the e powerful tools. For example, by 
fusing a TET catalytic domain with a zinc finger or TALE proteins, the target gene could 
be rapidly demethylated for reactivation.77, 78 Moreover, epigenome editing can be used 
to investigate the epigenetic code on histone considering that a same type of modification 
yet at different residuals might cause dissimilar outc mes. To this end, it has been found 
that demethylating H3K4 or methylating H3K9 could both achieve gene suppression.79, 80 
More recently, upon separating the targeting and effector domains and fusing them with a 
pair of light-sensitive proteins repectively, loci-specific histone modifications could be 
manipulated on demand by remote illumination.81 Thanks to the striving efforts for tool 
optimization, precision epigenome editing is striding nto a new era and being adapted for 




Figure 1.9 Next generation of epigenome-editing tools c mbining DNA-targeting mod-
ules and epigenetic effectors. (figure adapted from eference [75]) 
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CHAPTER 2.  UTILIZING REAL-TIME DYNAMICS OF MBD3 TO SENSE ACTIVE 
DNA DEMETHYLATION 
2.1 Introduction 
Global DNA hypomethylation, i.e., a genome-wide reduction in 5mC, is one of the 
most characterized epigenetic anomalies in cancer. However, it is immensely unclear on 
the triggering mechanisms for such an extensive DNA demethylation, which has become 
a stumbling block to our in-depth understanding of oncogenesis. Recently, a growing 
body of evidence has noted that loss of 5hmC also manifested in a number of cancers.83, 
84 In the paradigm of active DNA demethylation, 5mC is depleted through a series of ox-
idization to 5hmC, 5fC, and 5caC.85 The concurrent decrease of 5mC and 5hmC in tumor 
cells indicates that the cancerous DNA hypomethylation might be markedly attributed to 
an active process involving TET enzymes.10, 22  
Hypoxia is the typical microenvironment for solid tumors featuring excessive cell 
growth. As demonstrated before, low oxygen tension is critical for the maintenance of 
malignant tumorigenic cells (or cancer stem cells) that are responsible for a fatal tumor 
progression and metastasis.86 This hypothesis was indirectly supported by a study show-
ing that culturing human fibroblasts under hypoxia could more efficiently reprogram the 
cells to induced pluripotent stem cells.87 Complementary to the finding that cancer stem 
cells possess a much lower DNA methylation compared to physiologically differentiated 
cells, another line of research has revealed that hypoxic stress could evoke a substantial
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DNA demethylation in cancer cells and tissues.88, 89 These reports collectively suggest 
that hypoxia may be closely related to active DNA demethylation in tumorigenesis. To 
fully establish this connection, a cost-effective mthod for rapid quantification of all cy-
tosine modifications in trace amount of DNA is needd. Although techniques including 
liquid chromatography-mass spectrometry (LC-MS) andhigh-throughput next-generation 
DNA sequencing provide unparalleled power for epigenetic research, they are laborious, 
time-consuming, and not ideal for multiplex detection.90 In this regard, an enhanced en-
zyme-linked immunosorbent assay (ELISA) is first developed to validate the hypoxia-
induced active DNA demethylation in HeLa cells.    
Furthermore, limited tools exist to capture the ongoi  DNA demethylation in single 
cells. In the following work, with single-molecule FCS the process of active DNA de-
methylation is successfully captured by monitoring the real-time dynamics of MBD3 pro-
tein in living HeLa cells exposed to hypoxia. Among the MBD family members, MBD3 
possesses the lowest binding affinity with DNA methylation site due to the residual muta-
tions in its DNA-binding motif (Figure 2.1), which property makes MBD3 a candidate 
molecule to be detached from chromatin when the occupied CpG site is undergoing an 
enzymatic conversion. For active DNA demethylation t  proceed, the already existing 
5mC and 5hmC need to be enzymatically converted to 5fC or 5caC (suitable substrates 
for TDG-mediated BER). As a binding protein for both 5mC and 5hmC, MBD3 is ex-
pected to promptly dissociate from DNA in order to expose the modified cytosine; oth-
erwise its steric hindrance would impede the action of TET and TDG proteins. Hence, 
timely detection of the subtle changes in the MBD3 diffusion – the transition from bound 
to unbound state – provides an elegant solution to sense the process of active DNA de-
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methylation. FCS is a single-molecule approach thatcan conveniently quantify protein 
diffusion with resolution down to microseconds. With this temporal sensitivity, the accel-
erating MBD3 diffusion in the cell nucleus is proposed to be a precursory event for active 
DNA demethylation.  
 
 
Figure 2.1 Comparison of the core DNA-binding motifs in the major MBD proteins. The 
five key residues for substrate recognition are highlighted in light blue. The K30H/Y34F 
substitutions in MBD3 are highlighted in dark grey. The structural alignment for MBD2 
(PDB ID: 2KY8) and MBD3 (PDB ID: 2MB7) is generated with PyMOL.   
 
2.2 Methods and Materials 
2.2.1 Cell Culture, Plasmid Transfection, and Hypoxia Induction 
HeLa cells were routinely cultured in DMEM/F-12 medium supplemented with 10% 
fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin in a 37°C humid-
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ified incubator supplying 5% CO2. The pGFP-MBD3 plasmid was a kind gift from the Dr.
Adrian Bird’s group (University of Edinburgh, UK) and transfection was conducted with 
Lipofectamine LTX & Plus reagents (Life Technology). Before transfection, 5 × 104 cells 
were seeded onto a sterilized No.1 coverslip (VWR International) placed in 12-well plate 
with 2 mL fresh culture medium. After the cells reached 70-80% confluence the medium 
was replaced with antibiotics-free, low-serum medium for another 24 h culture. Then 100 
ng plasmid DNA, 2.5 µL LTX reagent, and 0.1 µL Plus reagent were dissolved in 200 µL 
Opti-MEM medium and incubated for 10 min before adding to the culture well. Transfec-
tion lasted for 24 h before hypoxia induction. Since FCS measurement requires an opti-
mal concentration ranging from hundreds of pM to nM, the cells selected for data collec-
tion have an average concentration of 80-120 nM MBD3-GFP expressed in their nuclei.    
Acute hypoxia was induced with 1 mM sodium dithionite (Na2S2O4, Sigma) to fast 
deplete dissolved oxygen in culture medium, which could efficiently lower the pO2 to 10 
Torr whereas 100% N2 could only lower the pO2 to 30-60 Torr.
91, 92 The pH of medium 
was re-adjusted to 7.4 by HEPES to buffer the acidifi at on potential of Na2S2O4. To 
maintain the hypoxic condition, medium containing Na2S2O4 was changed every 8 h. 
 
2.2.2 Enhanced ELISA for Quantification of DNA Methylation Marks 
On the basis of conventional ELISA that takes use of primary and secondary anti-
bodies, a third layer of signal amplification is designed for an enhanced ELISA by conju-
gating secondary antibody with biotin. When antigen is present, streptavidin coupled to 
multiple horseradish peroxidase (HRP) molecules would be specifically enriched (Figure 
2.2). For a 96-well assay plate, a maximum of 200 ng DNA could be input for analysis, 
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from which 5fC and 5caC are hard to be detected (less than 0.01% in genomic DNA). 
With this optimized ELISA, all the four types of cytosine modifications can be simulta-
neously quantified in the same plate.  
 
 
Figure 2.2 Schematic of the enhanced ELISA utilizing the biotin-avidin coupling. 
 
2.2.3 Biotinylation of Secondary Antibody 
Secondary antibodies in PBS were labeled with 50-fold molar excess of succin-
imidyl-6-[biotinamido]-6-hexanamidohexanoate (NHS-LC- C-biotin, Pierce) dissolved 
in DMSO. The reaction was performed in 10 mM phosphate buffer with 150 mM NaCl 
(pH = 7.4) at room temperature for 1 h and the biotinylated antibody was purified by di-
alysis and size exclusion chromatography with Sephadex G-15 gel column (gel volume: 
10 mL). The product was then concentrated and stored at 4°C until use. 
 
2.2.4 Conjugation of Streptavidin with HRP 
Streptavidin (Prozyme) and HRP were respectively coupled with succinimidyl 6-
(3[2-pyridyldithio] propionamido) hexanoate (LC-SPD, Pierce) and succinimidyl-4-(N-
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maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaprote) (LC-SMCC, Pierce) – both 
in the molar ratio 1:50 – at room temperature for 1 h. The LC-SPDP was treated with di-
thiothreitol (DTT, 10 mM) for activation at room temperature for 30 min. The thiolated 
streptavidin and maleimide-activated HRP (molar ratio 1:5) were purified with Sephadex 
G-15 gel filtration (pre-equilibrated in 5 mM EDTA) and then immediately mixed. The 
conjugation was carried out with gentle shaking at room temperature for 2 h. This protein 
product was stored at 4°C until use. 
 
2.2.5 DNA Extraction and ELISA Quantification 
DNA from HeLa cells was extracted with DNeasy Kit (Qiagen). Purified DNA in 
100 µL TE buffer (50 ng for 5mC, 200 ng for 5hmC, 5fC, and 5caC) was added to each 
polystyrene plate microwell followed by mixing with 100 µL DNA coating solution 
(Pierce) at room temperature for 2 h with gentle agitation. The substrate DNA was then 
washed three times with 300 µL of DI water in the microwell. To block residual surfaces, 
the microwell was treated with 0.5% (w/v) casein dissolved in PBS (200 µL) at 37°C for 
1 h. Primary antibodies used in this study include: mouse anti-5mC-IgG (Eurogentec), 
rabbit anti-5hmC/5fC/5caC-IgG (Active Motif). An amount of 0.5 µg/mL of primary an-
tibody diluted in PBS containing 0.5% casein (100 µL) was added and then 1 µg/mL of 
biotinylated secondary antibody (100 µL) was reacted with the primary antibody. To 
form avidin-biotin complex, 0.5 µg/mL of streptavidin-HRP conjugate (100 µL) was fi-
nally added into the microwell. For signal generation, 200 µL colorimetric substrate mix-
ture [50 mM sodium acetate buffer (pH = 5.1) : 1% (w/v) TMB : 3% (v/v) H2O2 = 1,000 : 
10 : 1 as volume ratio] was applied for 15 min at room temperature followed by 50 µL of 
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2 M sulfuric acid to stop the reaction. The optical intensity was measured by a Versa-
maxTM absorbance microplate reader (Molecular Device). As shown in Figure 2.3, the 
limit-of-detection (LOD) of enhanced ELISA is at least ten-fold lower than that of con-
ventional ELISA when using a standard DNA with 16% of the sequence as 5caC. Ap-
proximately 2 pg standard DNA (equivalent to 0.0016% 5caC in 200 ng genomic DNA) 
can be detected with enhanced ELISA whereas 20 pg standard DNA cannot generate a 
readable signal by conventional ELISA. 
 
 
Figure 2.3 Comparison of signal amplification between the conventional and enhanced 
ELISA for detection of 5caC-containing standard DNA. 
 
2.2.6 Instrumentation for FCS 
FCS was performed by using a scanning confocal time-resolved microscope (Micro-




























power output of excitation was precisely controlled at the µW level by a Sepia PDL 808 
driver to prevent phototoxicity. The laser beam was delivered to the sample stage through 
an apochromatic water immersion objective lens (60×, NA 1.2, Olympus) and the emitted 
fluorescence was collected by the same objective lens, after which the scattered excita-
tion light was cleaned by a dual-band dichroic (z467/638rpc, Chroma). A 50 um pinhole 
was employed to block the off-focus photons and the emission signal was finally separat-
ed by a band-pass filter (500-540 nm, Chroma) before reaching a SPAD detector (SPCM-
AQR-14, PerkinElmer). Information of each collected photon was stored in a time-tagged 
time-resolved (TTTR) mode (TimeHarp, PicoQuant) in which a time stamp was assigned 
to record the photon arrival time after the laser pulse.  
 
2.2.7 Data Analysis for FCS 
For live-cell FCS measuring nuclear proteins, two biophysical models are often ap-
plied to fit the autocorrelation function and characterize the molecular diffusion. The first 
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where α is the correcting factor to offset the diffusion hi drance caused by the crowded 
environment in cell nucleus. The other one is two-component 3D diffusion model: 
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where y is the fraction of bound molecules. In experiments of probing MBD3-GFP, both 
models were considered and tested as necessary to minimize the fitting residual (χ2) in 
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least-square regression algorithm. When fitting with two-component 3D diffusion model, 
a reference value for freeDτ was predetermined from the cytoplasmic MBD3-GFP.  
In parallel, the raw autocorrelation data were also nalyzed by the maximum entropy 
method for FCS (MEMFCS) to validate the robustness of FCS measurement. MEMFCS 
is a multi-component model to simultaneously minimize χ2 and maximize entropy S 
without a fitting priori.93 The MEMFCS output thus is a continuous distribution of Dτ  
instead of a presumed number of diffusing components (Figure 2.4). The G(τ) function in 
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. MEMFCS is particularly useful because of its capability to 









2.3.1 Active DNA Demethylation under Hypoxia 
To verify the type of DNA demethylation under acute hypoxia, all the four cytosine 
derivatives (i.e., 5mC, 5hmC, 5fC, and 5caC) were quantified by enhanced ELISA (Fig-
ure 2.5A). In 8 hours a global reduction of all modifications was noted, indicating the oc-
currence of active DNA demethylation. From the decreasing patterns of 5fC and 5caC, 
two peak periods of active DNA demethylation were suggested: the first and the last 8 
hours intermediated by a plateau period. During the peak periods, the active demethyla-
tion pathway is in full action because 5fC and 5caC are massively depleted by the TDG 
enzyme (Figure 2.5B). Considering the heterogeneous cellular responses to the hypoxic 
stress, these two demethylation periods might be attributed to distinct cell populations, 
i.e., hypoxia-sensitive and hypoxia-insensitive cells, in which the demethylation rates are 
not synchronous. The 8-16 h plateau period representing a flat change in the levels of 
5hmC/5fC/5caC implies a transition, regarding the contribution to the global hypometh-
ylation, from hypoxia-sensitive cells to hypoxia-insensitive cells. Although precise quan-
tification of 5fC and 5caC is difficult, the enhanced ELISA is capable of precisely deter-
mining as low as 1.7% of genomic 5mC and 0.027% of genomic 5hmC in HeLa cells 
(Figure 2.6), which is in excellent agreement with previous reports and validates the de-




Figure 2.5 Multiplex quantification of 5mC, 5hmC, 5fC, and 5caC indicates a hypoxia-
induced active DNA demethylation. (A) Normalized quantities of these four DNA meth-




Figure 2.6 Quantitative changes of 5mC and 5hmC under hypoxia. 
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2.3.2 MBD3 Detachment as Putative Indicator for Active DNA Demethylation 
The diffusion characteristics of MBD3-GFP in normoxia cells were determined by 
FCS: 14.49 ± 0.40 ms in nucleus and 3.10 ± 0.27 ms in cytoplasm. The much slower dif-
fusion in nucleus, as expected, was due to the association with DNA methylation site and 
other epigenetic co-factors. The diffusion rate of MBD3-GFP was further compared when 
hypoxia or 3 µM decitabine treatment (agent inducing passive DNA demethylation) (Fig-
ure 2.7) was applied. Decitabine achieves a demethylation effect by incorporation into the 
newly synthesized DNA strand and trapping DNMT1, and so it would not influence the 
already bound MBD3 in a relatively short time (e.g., within one to two cell cycles). Con-
sistently, after 1 day treatment with decitabine th average diffusion time of MBD3-GFP 
(13.43 ± 0.57 ms) was nearly the same as in control condition whereas a significantly 
faster diffusion time (9.89 ± 0.54 ms) was observed in hypoxic cells after 20 hours (Fig-
ure 2.8).   
 
 
Figure 2.7 FCS measurement for the MBD3-GFP diffusion in single living cells. (A) Da-
ta were collected from cell compartments with a prope  MBD3-GFP expression, followed 





Figure 2.8 Summary of the MBD3-GFP diffusion times (mean + S.E.M., n > 50). Statis-
tical significance was determined by ANOVA (p = 1.35 × 10-8). 
 
2.3.3 Diffusion of MBD3 in Hypoxia-Sensitive and Hypoxia-Insensitive Cells 
Following establishing the MBD3 diffusion as an indicator for active DNA demeth-
ylation, further experiments were performed to inspect its detailed behavior during the 
period of hypoxia. Interestingly, based on the MBD3 diffusion, two groups of cells can 
be distinguished in the first 4 hours of hypoxia. Despite that the majority of cells did not 
show a radical MBD3 detachment (diffusion time is about 14 ms), in ~30% of the cells 
the diffusion time of MBD3 displayed a steep reduction (diffusion time = 2.95 ± 0.36 ms). 
From the microscopic images, the latter group of cells exhibited the morphological prop-
erties akin to acutely damaged cells (Figure 2.9A), which was later confirmed by the pro-
pidium iodide (PI) uptake experiment (data not shown). Hence, these cells were termed 
as hypoxia-sensitive cells. Since the viscosity of nucleoplasm is nearly identical to that of 
cytoplasm,94 it can be inferred that MBD3 quickly and completely dissociated from the 
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DNA binding sites in hypoxia-sensitive cells. On the contrary, the diffusion of MBD3 in 
other hypoxia-insensitive cells experienced a mild and gradual detachment process, as 
inferred from the slow shift in the distribution ofdiffusion times (Figure 2.9B). Even af-
ter 24 hours, MBD3 in these cells did not seem to be fully detached (diffusion time = 
9.80 ± 0.75 ms) (Figure 2.9C). This phenomenon indicates a gentle weakening of the 
MBD3-DNA association, probably due to a retard activation of the demethylation path-
way (i.e., time required for an enhanced expression of TET and TDG proteins by hypox-
ia-inducible factors or pathways). Taken together, it can be concluded that the hypoxia-
induced active DNA demethylation leads to different diffusivities of MBD3 based on the 
cell state and susceptibility. Hypoxia-sensitive cells predominantly contribute to the ini-
tial, massive DNA demethylation in the population while hypoxia-insensitive cells are 
involved in the long-term, chronic DNA hypomethylation. Notably, the detachment of 
MBD3 serves as a sensitive measure of active DNA demethylation that could result in a 
premature cell death, especially to hypoxia-sensitive cells. Starting from the plateau peri-
od, the counts representing fully detached MBD3 in FCS measurements substantially de-
creased from ~30% to ~10% (Figure 2.9C, inset), implicating the elimination of severely 





Figure 2.9 Time-course change of the MBD3 diffusion in hypoxia-sensitive and hypoxia-
insensitive cells. (A) Morphology of the cells responding variedly to hypoxic stress. (B) 
The gradual shift of the MBD3 diffusion in hypoxia-insensitive cells. (C) Summary of the 
diffusion characteristics (by ANOVA tests). Percentage of the measurements representing 
hypoxia-sensitive cells is provided (inset).   
 
2.4 Discussion 
Even though global DNA hypomethylation has been characterized as one of the typi-
cal epigenetic events that drive a cancerous transformation, increased research emphasis 
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has been placed on the mechanistic understanding of promoter hypermethylation in tumor 
suppressor genes. As the oxidation of 5mC and its role in DNA demethylation is being 
elucidated, scientists start to recognize that the dynamic turnover of DNA methylation 
plays a pivotal role in embryogenesis, differentiation, and oncogenesis. This notion raises 
the necessity of inspecting DNA demethylation in single living cell. 
Utilizing single-molecule fluorescence techniques, this study paves the way for stud-
ying active DNA demethylation by monitoring the diffusion rate of MBD3 in real time, 
which is also the pioneering report on the spatiotemporal behavior of MBD proteins in 
single living cells. In contrast to other MBD proteins that have an nM-level dissociation 
constant (Kd) with DNA methylation site, the Kd between MBD3 and its binding substrate 
is at the µM level.35 Hence, MBD3 is more sensitive to be detached from chromatin in the 
cells exposed to a triggering stimulation for active DNA demethylation, while the in vivo 
binding substrates preferred by MBD3 needs further investigation. FCS has the quantita-
tive ability to sense minute changes in the diffusion of intracellular biomolecules and thus 
is a fitted tool to explore the dynamics of DNA demethylation. Under acute hypoxia, ac-
tive DNA demethylation is initially characterized by an intense detachment of MBD3 in 
hypoxia-sensitive cells, leading to the first demethylation peak and premature cell death 
within the first 4-8 hours. In hypoxia-insensitive c lls the demethylation process is more 
relaxed as reflected by the gradual increase in the MBD3 diffusion. To maintain a natural 
cell state and function, all cytosine derivatives have to be maintained at a tolerable level, 
partly achieved by the protection by MBD3 at relevant sites. Previous studies have shown 
that depletion of MBD3 could cause the mice to die in arly embryogenesis, signifying 
the importance of MBD3 in sustaining the overall abundance of DNA methylation.44 Fu-
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ture research may be focused on obtaining a high-resolution distribution landscape of all 
MBD proteins in the human genome and determining the MBD-dependent susceptibility 
to active DNA demethylation. In addition, the connections among epigenomic reshaping, 
hypoxic tolerance, and oncogenic evolution await more in-depth research (Figure 2.10). 
 
 
Figure 2.10 Influence of hypoxia on DNA methylation a d the fate of cancer cells. 
 
As the sophisticated DNA demethylation network is becoming more understood, it 
elicits a relevant question: does the hypoxia-induce  demethylation reaction terminates at 
5hmC? In human cells the removal of 5hmC could be processed by two possible mecha-
nisms: 1) through deamination of 5hmC to 5hmU (5-hydroxymethyluracil) by AID and 
APOBEC enzymes, followed by BER; 2) or the TET-TDG-mediated oxidation and BER. 
43 
 
Evidently, data from enhanced ELISA supports the latt r pathway in that 5hmC, 5fC, and 
5caC are concurrently reduced along with 5mC. Moreover, the detachment of MBD3 in-
dicates the TDG-mediated BER that involves a physical removal of cytosine derivatives. 
However, which specific TET proteins involved in this process remains to be identified. 
Previously, most of the cancerous hypomethylation were found in the short and long in-
terspersed nuclear elements (SINEs and LINEs) as well as repeat sequences that were 
long thought as non-coding “junk” DNA.95, 96 Revealed by the Encyclopedia of DNA El-
ements (ENCODE) project in 2012, nearly 80% of the human genome is actually func-
tional,97 necessitating re-interrogation of the epigenetic state at these regions. In recogni-
tion of that the patterns of DNA hypomethylation could be largely varied in different 
cancers, an emerging thought is to study the DNA demethylation in a locus-specific man-
ner so that targeted intervention or therapy can be designed. To fulfil this, methodologies 
to capture the key moments in a demethylation event and to differentiate heterogeneous 






CHAPTER 3. BEHAVIOR AND FUNCTION OF MBD3 IN DNA METHYLATION 
HOMEOSTASIS 
3.1 Introduction 
DNMTs are responsible for adding methyl marks to CpGs; however, the traditional 
view of classifying the three major human DNMTs to maintenance DNMT and e novo 
DNMT appears to be challenged by cumulative evidence that expounds on a considerable 
overlap between their functions,98-100 which in turn inspires a revisiting of the existing 
knowledge about the DNA methylation homeostasis. Over the past decade it has been 
observed that the maintenance of DNA methylation rarely follows a rigorous CpG-by-
CpG fidelity, but adopts a stochastic model in which only the average density of DNA 
methylation within a certain region of sequence needs to be conserved.101, 102 To achieve 
a balance, the twin forces of methylation and demethyla ion contend in equilibrium but 
also work by side. Although the TET family proteins are the only enzyme that catalyzes 
the active DNA demethylation in mammalian cells, they primarily enrich in germ cells 
and early embryogenesis instead of in somatic cells.103 In light of this, it is of great inter-
est to resolve the question on whether additional factors or machineries exist to facilitate 
the precision of maintenance methylation with limited TETs as well as to prevent a pos-
sible over-methylation by DNMTs in the DNA methylation homeostasis.   
MBD3 belongs to a family of nuclear proteins in close relation to DNA methylation, 
but it involves quite different chromatin association and regulatory mechanisms as com-
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pared with other MBD proteins.44, 104 In spite of sharing over 70% of its sequence with 
MBD2, MBD3 was found not to be a strong binding protein for 5mC.33, 105, 106 In fact, as 
a constitutive component in the Mi-2/NuRD complex, MBD3 preferentially localizes at 
CG-rich promoters and enhancers relating to active genes whose methylation state is 
poised to frequent turnovers.107, 108 More interestingly, it has been reported that overex-
pressing MBD3 could induce a global DNA demethylation,42, 109 and a co-localization of 
MBD3, MBD2 and DNMT1 could appear at the DNA replication foci to associate with 
hemi-methylated DNA.110 These intriguing findings motivate this study to re-evaluate the 
underpinning functions of MBD3 in the DNA methylation homeostasis.  
In previous chapters, the potency of single-molecul techniques in uncovering epige-
netic dynamics was introduced and the diffusion characteristic of MBD3 was successful-
ly correlated with active DNA demethylation by FCS. In this chapter, a comprehensive 
set of single-molecule fluorescence tools is applied to dissect the behavior of MBD3 from 
the cell cycle perspective. The research hypothesis r garding the MBD3-MBD2-DNMT1 
cooperation lies in the in vivo demethylating potential of MBD3 to buffer the activity of 
DNMT1 during DNA replication as contributing to the epigenetic inheritance of a loci-
specific methylation pattern. 
In order to obtain an in-depth understanding, several biophysical attributes of MBD3 
are characterized – intracellular dynamics, chromatin ssociation, binding stoichiometry, 
and molecular interactions in each stage of the cell cyc e. Fluorescence lifetime correla-
tion spectroscopy (FLCS), an elegant derivative of FCS, is first used to quantify the real-
time diffusion of MBD3 in different cell phases and the results suggest that MBD3 has 
distinct binding partners in the G1-phase and G2-phase. Furthermore, the DNA-binding 
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stoichiometry of MBD3 is analyzed by PCH that corroborates a salt-dependent “two-site 
sequential binding” mode in the G1-phase nucleus. In the G2-phase, the co-localization 
of MBD3, MBD2, and DNMT1 is verified with FLIM-FRET. When depleting MBD3 by 
siRNAs, the global DNA methylation increases along with promoter hypermethylation in 
a number of cell cycle-related genes. Altogether, this work constitutes a pioneer effort to 
revise the model of the DNA methylation homeostasis nd paves the way for future re-
search aimed to better interpret the epigenetic inher tance.  
 
3.2 Methods and Materials 
3.2.1 Cell Cycle Synchronization 
G1-enriched HeLa cells were obtained by treatment with 400 µM L-mimosine for 
20-24 h. To achieve a maximum of S-phase population, cells were blocked with 2 mM 
thymidine for 20 h and released in fresh medium for 10 h, followed by another 20 h thy-
midine blocking and then culturing with fresh medium for 2-6 h (early S-phase: 2 h; mid-
dle S-phase: 4 h; late S-phase: 6 h). Culture of G2-arrested cells was obtained by incuba-
tion with fresh medium containing 0.1 µg/mL Colcemid (Life Technologies) for 6 h after 
two rounds of thymidine blocking. Flow cytometry was used to validate the cell cycle 
synchronization.111 In general, cells were fixed with 70% ethanol first and stained with 
PBS buffer containing 20 µg/mL PI, 0.1% Triton X-100, and 200 µg/mL RNase A. The 
fluorescence intensity of PI in each single cell was determined by a FC500 MPL system 
(Beckman Coulter). At least 15,000 cells were collected for one measurement and the 
generated cell cycle histogram was fitted by the Watson pragmatic model in the Flowjo 
software (Figure 3.4A).  
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3.2.2 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Total RNA was extracted and reverse-transcribed with RNeasy Mini Kit (Qiagen) 
and iScript cDNA Synthesis Kit (Bio-Rad), respectively. Before cDNA synthesis, the ge-
nomic DNA was removed by DNase I. PCR reaction was performed in a StepOnePlus 
system using SYBR Green PCR Master Mix (Life Technologies). ∆∆Ct method was used 
to normalize the transcription of target genes to the internal control gene GAPDH. The 
PCR primers for GAPDH, DNMT1, DNMT3A, and DNMT3B were designed with the 
Primer-BLAST online tools (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 

















3.2.3 FLCS and PCH 
In FLCS, separating the “genuine” molecular diffusion from the overall fluctuation is 
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where τi is the characteristic decay lifetime of the ith component and ai is its amplitude. A 
filter function is applied to assign the probability contribution of a single photon to the 
autocorrelation function for the ith component with an optimal weight determined by its 
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=∑ , where L is the number of 
components, and the weight for each component could have an absolute value greater 
than 1 or be a negative value. These filter functios are numerically calculated by a ma-




Hence, the autocorrelation function for a specific species (i) can be expressed as:  























Taking advantage of the TCSPC filtering, a distorted autocorrelation fluctuation due 
to the detector noises (e.g., thermal noise, afterpulsing) and other parasitic noises (e.g., 




Figure 3.1 TCSPC filter function eliminates the impact of the short-timescale noises to an 
autocorrelation function. 
 
The basic theory and working mechanism of PCH is elaborated in Chapter 1.2.2. To 
test the PCH algorithm, Cy3 tetramer was successfully differentiated from Cy3 monomer. 
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In this experiment, a ten-fold concentrated solution of Cy3 monomers was prepared and it 
was impossible to distinguish it from the tetramer solution by simply comparing the en-
semble fluorescence intensities (otherwise the average brightness could give out an oppo-
site conclusion). However, by mathematically eliminat g the influence from the concen-
tration difference, the single-molecule brightness of Cy3 tetramers was determined to be 
almost four times of that of Cy3 monomers, thus verifying the power of PCH. 
 
 
Figure 3.2 In vitro demonstration of PCH. Ensemble fluorescence traces (left panel) with 
an integration window of 50 µs are translated to phton counting histograms followed by 
fitting with super-Poissonian algorithm (right panel), yielding single-molecule brightness. 
 
3.2.4 Immunofluorescence and FLIM-FRET 
Considering the sensitivity of FRET to the inter-molecule distance, to minimize the 
size effect from antibodies (~10 nm), the primary antibodies (anti-MBD1/MBD2/MBD3-
IgG, Abcam; anti-DNMT1-IgG, Novus Biologicals; anti-5hmC/5fC/5caC-IgG, Active 
Motif) were directly labeled with the FRET-pair dyes including: MBD3-Alexa488 (donor) 
and MBD1/MBD2/DNMT1/5hmC/5fC/5caC-Alexa555 (acceptor) by using APEX Anti-
body Labeling Kits (Life Technologies). For immunofluorescence staining, cells were 
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fixed with 4% ice cold paraformaldehyde (PFA) for 15 min and then rinsed three times 
with clean PBS buffer. Cell membrane was permeabilized with 0.4% Triton X-100 for 30 
min followed by rinse for 15 min. To stain 5hmC, 5fC, and 5caC, DNA was denatured by 
1 N hydrogen chloride at 37°C for 30 min. Cells were then blocked with PBS containing 
5% goat serum and 0.3% Triton X-100 for 1 h at room te perature. Primary antibodies 
were diluted 50-100 times in PBS containing 1% BSA and 0.3% Triton X-100 (to a con-
centration of ~5 nM) and incubated with cells overnight at 4°C. In the next day cells were 
rinsed 3 times with fresh PBS prior to FLIM imaging. The FLIM-FRET theory and in-
strumentation are elaborated in Chapter 1.2.2. For a 150 × 150 pixels FLIM image ob-
tained from one scanning, the laser dwelling time at ach pixel is about 0.8 ms that is far 
longer than most fluorescence lifetimes (ns-level). TCSPC can be generated from a single 
pixel or all the pixels in an image (Figure 3.3B); hence the FLIM measurement can reach 
single-molecule resolution if few fluorophores exist in one pixel.  
 
3.2.5 Co-Immunoprecipitation (Co-IP) and Western Blot 
Co-IP was conducted with the Pierce Co-IP Kit (Thermo Fisher Scientific) referring 
to an established protocol.116 In brief, anti-GFP monoclonal antibody (primary amine-free, 
Pierce) or control IgG was first immobilized using the AminoLink Plus coupling resin. 5 
× 106 cells transfected with MBD3-GFP in different cell phases were lysed (25 mM Tris, 
150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol; pH = 7.4) and about 1.5 mg pre-
cleared lysate was incubated with the antibody-coupled resin at 4°C overnight. After elu-
tion, the sample was analyzed by Western immunoblotting. The input proteins were sepa-
rated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
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followed by membrane transferring and incubation with the primary antibodies. The final 
signal was developed by Pierce Fast Western Blot Kit and SuperSignal West Pico Sub-
strate. 
 
3.2.6 Transfection of siRNA and Methylation Analysis 
MBD3 siRNA, scrambled siRNA, and transfection reagents for knockdown experi-
ments were obtained from Santa Cruz Biotechnology. 50 pmol siRNA was used for a 35 
mm Petri dish in which cells reached 70% confluence, according to the manufacturer’s 
instruction. Transfection lasted for 24 h followed by sub-culturing with normal fresh me-
dium for another 72 h. DNA from control and siRNA-treated cells was extracted and pu-
rified with DNeasy Blood & Tissue Kit (Qiagen), according to the manufacturer’s in-
struction. Global DNA methylation was quantified with MethylFlash Methylated DNA 
Quantification Kit (Epigentek). Briefly, 100 ng DNA was deposited to the bottom of the 
assay well and incubated with capture antibody and detection antibody, sequentially. The 
final colorimetric signal was normalized to a standrd input DNA to calculate the global 
methylation percentage. 22 genes participating in cell cycle progression were assessed for 
their promoter CGI methylation by using EpiTect Methyl II Signature PCR Array (Qi-
agen). The working mechanism for this assay is to digest an equal amount of DNA with 
methylation-sensitive endonuclease (the unmethylated DNA will be eliminated) or meth-
ylation-dependent endonuclease (the methylated DNA will be eliminated). Upon a PCR 
amplification with specific primers targeting the characterized CGIs of the chosen genes, 





3.3.1 Localization Preference and Cell Cycle-Dependent Expression of MBD3 
The localization preference of endogenous MBD3 was first probed via FLIM-FRET, 
to explore the association of MBD3 with the active demethylation products (i.e., the 5mC 
derivatives). From the results, a relatively weak interaction between MBD3 and 5hmC 
was noted while MBD3 exhibited a prominent co-localization with 5fC and 5caC (Figure 
3.3), which is consistent with the recent findings using conventional methods.106, 117 
However, this cannot fully rule out the possibility of MBD3 as a reader protein for 5hmC 
because: 1) FRET could be influenced by other factors such as the donor-acceptor orien-
tation; 2) the MBD3-5hmC interaction requires some other co-factors that might block or 
separate the antibody recognition sites or 3) this connection might be cell type-specific.105 
Nevertheless, this set of experiments provides partial evidence to the assumption that 
MBD3 associates with the CpGs experiencing active transition in their methylation state. 
This demethylation potential could be ascribed to the MBD3-mediated further recruit-





Figure 3.3 Localization preference of MBD3. (A) FLIM images of double-stained cells 
with directly labeled primary antibodies. (B) Fluorescence lifetime can be determined by 
fitting the TCSPC from the whole image (left panel), or single pixels to generate a histo-
gram (right panel). (C) FRET efficiencies between MBD3 and different 5mC derivatives. 
 
Next, the transcription of DNMTs and MBD3 in different cell phases was quantified. 
The qRT-PCR results show that all DNMTs start to increase in the S-phase and maintain 
their abundance till the G2-phase (Figure 3.4B), which validates the cell cycle-dependent 
expression of DNMTs.118 Although it is expected that the transcription of DNMTs should 
peak during the S-phase rather than in the G2-phase, two critical points to bear in mind 
are that 1) the DNA maintenance methylation is a del yed event subsequent to DNA rep-
lication119 and 2) in cancerous or transformed cells (e.g., HeLa cells here) the regulation 
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of DNMTs could become more lagged due to rapid cell pro iferation. Interestingly, ac-
companying with all DNMTs, the transcription of MBD3 also experiences a cell cycle-
dependent enrichment. This concurrent transactivation provides preliminary support for a 




Figure 3.4 Expression of MBD3 is concurrent with DNMTs in cell cycle. (A) Cells en-
riched in each cell phase were harvested for qRT-PCR. (B) Transcriptional levels are pre-
sented as mean with standard deviation (n = 4). One-way ANOVA was used to determine 
the statistical significance. 
 
3.3.2 The Mobility of MBD3 is Increasingly Constrained during the G1-S-G2 Transi-
tion 
After transfection, the intracellular diffusion of MBD3-GFP was characterized by 
FLCS. In non-synchronized cells, the diffusion rate of MBD3-GFP in cytoplasm is found 
to be much faster (diffusion time = 3.6 ± 0.4 ms) than that in nucleus (diffusion time = 
16.2 ± 1.9 ms), which is in agreement with the results in Chapter 2. The restricted diffu-
55 
 
sion of MBD3-GFP in nucleus could be attributed to tw  mechanisms: 1) integration into 
the larger Mi-2/NuRD complex and 2) association with the targeting chromatin site. The 
cell cycle-dependent diffusion of MBD3-GFP was then d termined. Compared to MBD3-
GFP in the G1-phase cells, MBD3-GFP in the S-phase and the G2-phase cells exhibits a 
drastically slower diffusion: diffusion times are 11.5 ± 0.6 ms (G1), 26.6 ± 1.3 ms (S), 
and 36.9 ± 2.1 ms (G2), respectively (Figure 3.5C). Moreover, an incremental adjustment 
for anomalous diffusion was noted in fitting the autocorrelation functions from the G1 to 
S and G2 transition, indicating a strengthened chromatin interaction. Considering that the 
molecular diffusion is negatively proportional to the hydrodynamic radius, the data from 
FLCS suggests that, starting from the S-phase, the MBD3-NuRD complex may further 






Figure 3.5 The mobility of MBD3 is increasingly restricted during the cell cycle progres-
sion. (A) FLCS data collection points from different cell compartments. (B) Autocorrela-
tion functions in different cell phases were obtained from cytoplasm (upper) and nucleus 
(lower). (C) Summarized diffusion statistics and significance test by ANOVA. Each col-
umn represents data from more than 15 cells (mean + S.E.M., n > 30). 
 
3.3.3  The DNA-Binding Stoichiometry of MBD3 Undergoes a Transition during the S-
Phase 
Following FLCS, the average single-molecule brightness of nuclear MBD-GFP was 
evaluated by PCH, which uncovered a gradual reduction in the copy number of MBD3-
GFP molecules along with the cell cycle progression (Figure 3.6A). To calibrate the GFP 
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brightness from different stoichiometry, a series of c ntrols were included: monomeric 
GFP in solution and in cell nucleus, toll-like receptor 9-GFP (TLR9-GFP), and MBD1-
GFP in live cells. In vitro GFP monomers were measured to establish the baseline bright-
ness that is 1341 ± 48 cpsm (counts per second per molecule) under a 2.5 µW excitation 
power (Figure 3.6B). Based on this value, about 8% of nonspecific dimerization was de-
termined in living cell nucleus. Then the obtained brightness from dimerizable proteins 
could be assigned to a proper composition of monomers and dimers. Referring to previ-
ous reports, TLR9-GFP and MBD1-GFP were respectively chosen as dimer and mono-
mer controls.120 From the PCH calculation, the dimer percentages for TLR9-GFP and 
MBD1-GFP are 78% and 2% in HeLa cells, irrespective of cell phases. Notably, the di-
mer percentage of MBD3-GFP implicates that its compsition stoichiometry experiences 
a cell cycle-dependent transition: from 84% in the G1-phase to 48% in the S-phase, and 
eventually to 16% in the G2-phase (Figure 3.6C). According to a recent study, MBD do-
main was able to dimerize at a single methylated CpG and this stoichiometric pattern was 
salt/cation-dependent.121 It was thus proposed that a low-salt environment could under-
mine the dimerization of MBD3 in living cells. By culturing G1-phase cells in hypotonic 
medium, the dimer proportion of MBD3-GFP was indeed r uced (Figure 3.6D). In the 
hypothesis of this study, the stoichiometric transition of MBD3 in cell cycle is driven by 
the cooperation among MBD3, MBD2, and DNMT1 in the DNA maintenance methyla-
tion, which can be combined with the FLCS findings: during the cell cycle progression, 
MBD3 is gradually incorporated into a larger protein complex (inferred from the slowed 
diffusion rate) so that gains a stronger binding affinity with chromatin (inferred from the 
increasing anomalous diffusion behavior). This single-molecule behavior implies that the 
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difference between the inter-molecule bonding strengths of MBD3-DNA and MBD3-
MBD2-DNMT1 mechanistically advance the stoichiometric ansition, for which the in-
tracellular microenvironment (e.g., local salt ions) may play a pivotal role.    
 
Figure 3.6 Single-molecule brightness analysis implicates a stoichiometric transition of 
MBD3. (A) PCH from nuclear MBD3-GFP in different cell phases. (B) Brightness of dif-
ferent GFP tagged proteins: pure GFP is the baseline co trol, TLR9-GFP is the dimer 
control, and MBD1-GFP is the monomer control. (C) Dimer percentage for each protein 
is calculated. (D) Hypotonic medium disrupts the dimer formation of MBD3-GFP in the 
G1-phase nucleus. 
 
3.3.4 MBD3, MBD2, and DNMT1 Act in Concert in DNA Maintena ce Methylation 
Despite that a number of methods, including Co-IP, affinity electrophoresis, pull-
down assay, and two-hybrid screening, are available for valuation of molecular interac-
tions; a grand challenge is on how to directly visualize such in situ information in its orig-
inal context. Super-resolution optical microscopy has overcome the diffraction limit im-
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posed by the physical law to achieve a sub-200 nm resolution for single-cell imaging, but 
the spatial scale (< 10-20 nm) for most protein-protein and protein-DNA interactions is 
still beyond that “super-resolution” scope. Hence, in this study FLIM-FRET was em-
ployed as a finer measure to probe the MBD3-related co-factors at the 10 nm scale. By 
directly labeling the primary antibodies, HeLa cells were double-stained and measured by 
FLIM in different cell phases (Figure 3.7A). As expcted, a cell-cycle dependent occur-
rence of FRET was noted in both the MBD3-MBD2 and the MBD3-DNMT1 combina-
tions, indicating a growing proportion of MBD3, MBD2, and DNMT1 assembled into a 
larger complex. In the G1-phase, MBD3-Alexa488 in the presence of MBD2-Alexa555 
has a slightly shorter lifetime (3.34 ± 0.06 ns) than that in the presence of DNMT1-
Alexa555 (3.45 ± 0.06 ns) (Figure 3.7B), confirming that some of the endogenous 
MBD3-MBD2 co-localization is cell cycle-independent.5, 122 In the control combination, 
no FRET signal was detected between MBD3-Alexa488 and MBD1-Alexa555 (Figure 





Figure 3.7 Co-localization of MBD3-MBD2-DMNT1 was asessed by FLIM-FRET. (A) 
Labeled primary antibodies were applied to target th  protein pairs (i.e., MBD3-DNMT1, 
MBD3-MBD2). FLIM images of MBD3-Alexa488 were obtained in different cell phases, 
with DNMT1 or MBD2 labeled by Alexa555. (B) Fluorescence lifetimes are presented 
with mean and stand deviation (n = 10 images), based on which FRET efficiencies can be 





Figure 3.8 MBD3 and MBD1 are not interactive in cell cycle. (A) Double staining was 
performed with directly labeled antibodies. (B) FLIM of MBD3-Alexa488 was collected 
in different cell phases. 
 
3.3.5 Insufficiency in MBD3 Disrupts DNA Methylation Homeostasis 
To inspect the functional involvement of MBD3 in the DNA methylation homeosta-
sis, a group of siRNAs specifically targeting the MBD3 expression were introduced into 
HeLa cells. Given the findings that MBD3 facilitated a hypomethylation for its binding 
sites, it was expected that cells would experience a global hypermethylation when MBD3 
was knocked down. Using quantitative immunoassay, the global level of DNA methyla-
tion in knockdown cells was found to increase from 1.66% to 2.34% after 72 hours (Fig-
ure 3.9B). Afterwards, the methylation levels of promoter CGIs in 22 cell cycle-related 
genes were evaluated since MBD3 has been discovered to gulate the cell cycle progres-
sion.123 The promoter CGIs of the selected genes, except BRCA2 and RAD9A, were de-
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termined to be extensively hypomethylated or unmethyla ed in HeLa cells, consistent 
with the ENCODE dataset (retrieved from https://genome.ucsc.edu/) and previous litera-
ture.124 After the MBD3 expression was suppressed, a ubiquitous elevation in the methyl-
ation of assessed CGIs was observed, though some changes were relatively subtle per-
haps due to the short period of knockdown (Figure 3.9C). In parallel, the global demeth-
ylation caused by overexpression of MBD3 was also confirmed (Figure 3.9). Concerning 
the importance of MBD3 to the Mi-2/NuRD function and DNA maintenance methylation, 
the cell cycle progression is subjected to dysfunctio  when MBD3 is deregulated. There-
fore, the cell-phase distribution was re-examined an  it indicated a difficulty for MBD3-
insufficient cells to pass the G1/S checkpoint (Figure 3.9D), resembling a G1-phase arrest 
upon depletion of Mi-2/NuRD or DNMTs.125-127 Overall, this line of results supports the 
hypothesis that the demethylating potential of MBD3 plays a critical role in sustaining 





Figure 3.9 Insufficiency in MBD3 disrupts the DNA methylation homeostasis. (A) The 
MBD3 siRNAs were introduced to HeLa cells for knockdown. (B) 72 hours after knock-
down, the global DNA methylation was determined with immunoassay (n = 3), (C) the 
promoter CGIs methylation of 22 cell cycle-related genes was quantified with PCR arrays 
(n = 3), and (D) the cell cycle distribution was examined with flow cytometry. 
 
 





Achieving the DNA methylation homeostasis necessitates the interplay amidst mul-
tiple molecules and mechanisms. For a single nucleosome that covers about 200 bp DNA 
(including the linker), statistically 3-10 CpGs are included and the average extent of 
methylation marks should be inherited over generations. In order to retain such a steady 
methylation for a given region, a unified stochastic model was recently proposed102:  
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Perceived from the model, the steady-state methylation level at a specific locus (,i ssmθ ) 
is synergistically determined by several variables – the rate of cell division (D), the effi-
ciency of maintenance methylation (imainf ), the rate of demethylation (
i
demetr ), the rate of 
















Derived from the above equation, the forces between demethylation and methylation 
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Upon incorporating the activity (ir ) of the DNA methylation-related enzymes, it can 
be roughly defined: 1 2
i i i
main DNMT MBDf r r∝ × , 3 3
i i i
met DNMT A DNMT Br r r∝ + , 3
i i i
demet TETs MBDr r r∝ × . In 
the G1-phase, MBD3 tends to locate at the active gen s and protect their hypomethylated 
status to avoid DNMT3 invasion. In the S-phase and G2-phase, DNMT1 – together with 
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DNMT3 – accomplish the DNA maintenance methylation, whereas no experiments have 
observed the real-time participation of TETs in this process. Yet without a protective or 
proofreading mechanism, the delicate DNA methylome would be fairly vulnerable to a 
non-equilibrium whenever DNMT1 overacts (i.e., 1imainf > ). In line with previous reports, 
this study reveals the dynamic behavior of MBD3 andits importance to the DNA methyl-
ation homeostasis: when cells enter cell cycle, a proportion of MBD3 and MBD2 would 
co-localize with DNMT1 to offer a regulatory “symbiosis” for the ongoing DNA mainte-
nance methylation (Figure 3.11A). As newly discovered methylation derivatives, 5fC and 
5fC emerge to have their independent regulatory functio s,128, 129 and one potential func-
tion for MBD3 in the DNA methylation homeostasis is to mark their existence on the pa-
rental DNA strand and pass down to the daughter strand (Figure 3.11B). Besides DNA 
methylation, the MBD2/3-associated Mi-2/NuRD can further facilitate nucleosome re-
modeling and histone modification in the newly synthesized chromatin. Also in light of 
the uncovered dynamic behavior of MBD3, it can be inf rred that the occupancy sites by 
MBD3 are varied in different cell phases, which may explain the divergent observations 





Figure 3.11 Dynamic behavior of MBD3 in the DNA methylation homeostasis. (A) In the 
G1-phase, MBD3-NuRD adopts a “two-site sequential binding mode” at its binding CGIs 
and maintains a hypomethylated state. kd1 and kd2 denote the two dissociation constants 
for the homodimer. As DNA starts to replicate, the newly synthesized hemi-methylated 
DNA intends to inherit the methylation density from the parental template, catalyzed by 
DNMTs (mainly DNMT1). A proportion of MBD3 and MBD2 would cooperate with 
DNMT1 to complement the maintenance accuracy. kd3 denotes the dissociation constant 
for the heterodimer. (B) When MBD2 and DNMT1 are re-establishing the landscape of 
5mC, the demethylating potential of MBD3 can facilitate preserving those 5mC deriva-
tives (i.e., 5hmC, 5fC, and 5caC), providing a balancing force in the DNA methylation 
homeostasis.  
 
The core region sequence for DNA recognition and binding is highly conserved 
among human MBD members. To date some already identified residues critical for the 
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MBD-DNA coupling include VAL20, ARG22, LYS30, TYR34, ARG44 and SER45,32, 33 
in which the arginine residues determine a hydrogen bond and cation-π interaction-based 
“stair motif” association with CpGs.34 Although MBD3 is highly identical to MeCP2 and 
MBD2 in that core region, the two residual mutations (K30H and Y34F) at the binding 
interface undermine the interaction specificity between MBD3 and 5mC. Corresponding 
to a recent research showing that MBD3 preferably localizes to the active epigenetic loci, 
such as enhancers and promoters, herein the FLIM-FRET approach confirms an i  situ 
interaction between MBD3 and the 5mC-oxidized derivatives (i.e., 5hmC, 5fC and 5caC 
that are difficult to be detected with traditional DNA-sequencing methods), to support the 
participation of MBD3 in the DNA demethylation and gene activation. 
The binding stoichiometry between MBD domain and its targeting site was elusive 
and even controversial as in different studies. Until very recently, a “two-site sequential 
binding mode” has been biochemically evaluated and it demonstrated that the MBD-
mediated DNA binding would tolerate a homodimeric stoichiometry at a single CpG but 
with dissimilar dissociation constants: approximately 80 nM for the first MBD and 5 µM 
for the second one.121 Moreover, a low salt concentration could substantially compromise 
the MBD to differentiate (methylated)CpG from random DNA sequences as monovalent 
cations are crucial to suppress the non-specific binding. This explains why the homodi-
meric state of MBD3 in the G1-phase got significantly depleted when a hypotonic medi-
um was applied. On the contrary, MBD1 was found to exist predominantly in a mono-
meric state, which might be due to the distribution of MBD1 in the highly condensed het-
erochromatin where the low-affinity dimerization is physically hindered. One interesting 
finding requiring future elucidation is about the MBD3 stoichiometric transition from the 
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G1-phase to the G2-phase, if this transition is not only enforced by a mechanical separa-
tion along with the double-helix disentanglement in he S-phase. Theoretically, the coop-
eration of MBD2-MBD3-DNMT1 aids in achieving the homeostatic DNA maintenance 
methylation, while the detailed mechanism to form such a multi-component complex is 
challenging to resolve. MBD2 and DNMT1 have a structural base to co-localize because 
they could firmly bind with hemi-methylated DNA. For a further incorporation of MBD3, 
additional actions might be needed. One is through other epigenetic modifications such as 
histone acetylation. MBD2, in the context of Mi-2/NuRD, can induce a local histone hy-
poacetylation to subsequently attract MBD3-NuRD. Another way is through the coiled-
coil interaction. The key helix domain to form coiled-coil oligomers is highly conversed 
among MBD proteins, though a stable MBD2-MBD3 heterodimer was hard to detect by 
gel filtration analysis.130 However, considering the fact that the coiled-coil interaction is 
contingent on the protein conformation as well as the surrounding physicochemical fac-
tors,131 it cannot eliminate the possibility of a cell cycle-dependent coiled-coil MBD3-
MBD2 interaction. In addition, as a core subunit in he Mi-2/NuRD, p66α can stably oli-
gomerize with either MBD2 or MBD3,130, 132 an indirect route to link MBD3 and MBD2 
could be involved – in the context of a multimer bridged by p66α or other coiled-coil 
domain proteins. Notably, the dissociation constant for coiled-coil mediated interactions 
can reach the level of ~10 nM (a much stronger affinity than the MBD-DNA binding), 
thus conducive to the disintegration of MBD3 homodimers. The primary concern for this 
assumption is how the coiled-coil interaction gets inhibited in the G1-phase. Last, in the 
process of recruiting biomolecules to achieve the maintenance methylation, the potential 
contribution from those classical DNA replication-related proteins, such as PCNA and 
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UHRF1, should not be overlooked. Further efforts can be placed in understanding the 
triggering mechanism for this stoichiometric transition and profiling the detailed interac-
tome.   
From phenotypic studies, MBD3 has been shown to play a deterministic role in em-
bryogenesis,44 pluripotency,133 differentiation,112 reprograming,134 and a variety of dis-
eases,39 highlighting its functional importance. Disrupting the expression of MBD3 une-
quivocally results in abnormal DNA methylation, but an in-depth exploration is lacking. 
This study, combining single-molecule probing with biological experiments, opens a new 
window to research the underlying mechanistic connections. The close relation between 
MBD3 and DNA demethylation gives rise to a cell cycle-dependent protein behavior and 
serve as a pivotal balancing strength to merit the DNA methylation homeostasis. By high-
lighting the location of 5mC derivatives, this unique feature of MBD3 could not only im-
prove the precision and efficiency of TETs but also constitute a protective mechanism to 





CHAPTER 4. REGULATORY LANDSCAPE AND CLINICAL IMPLICATION OF 
MBD3 IN HUMAN MALIGNANT GLIOMA 
4.1 Introduction 
The deadly form of intracranial malignant gliomas, i.e., the World Health Organiza-
tion (WHO) grade III-IV tumors, constitutes a heavily socioeconomic and healthcare 
burden. Today, even with significant advances in surgery, radiation therapy, and chemo-
therapy, yet the median survival for glioma patients, especially for those who are diag-
nosed with the most aggressive glioblastoma multiforme (GBM, grade IV) is extremely 
poor. A multitude of factors are involved in gliomagenesis, and so far enormous efforts 
have been invested in seeking clinical biomarkers fo  a better patient stratification and 
therapeutic management. As similar in other cancers, genetic mutations, epigenetic aber-
rations, environmental stress, signaling malfunction, and immunologic dysfunction syn-
ergistically contribute to the etiology of human malignant glioma.135-137 For GBM pa-
tients receiving gross total surgical resection and effective adjuvant treatments, the 5-year 
survival rate is only 0.05% to 4.7% upon diagnosis,138 which imperatively necessitates 
more in-depth and comprehensive research. 
Although epigenetic aberrations have been uncovered as a driving force in a large 
number of human diseases, its mechanistic correlation with malignant glioma is less ex-
plored. As a key modulator, DNA methylation, i.e., the addition of a methyl group to the 
5-carbon of cytosine, epigenetically dictates the downstream transcription when accumu-
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lating at the CpG island of a gene promoter.4 In the oncogenic process, extensive altera-
tions regarding the quantity and distribution of DNA methylation have been observed.139 
Hence, the DNA methylation homeostasis is essential to prevent a cancerous transfor-
mation and require a delicate cooperation among numerous molecules and factors, in-
cluding MBD proteins.140 In contrast to other typical MBD proteins (e.g., MBD2 and 
MeCP2) that specifically associate with 5mC for gene repression, MBD3 evolves to gain 
a functional diversity. It has been found that MBD3 can either up-regulate or down-
regulate its influential genes under particular circumstances.107 As a core subunit of the 
Mi-2/NuRD complex, MBD3 also participates in the regulation of nucleosome remodel-
ing and histone acetylation.5 In Chapters 2 and 3, the significance of MBD3 in the active 
DNA methylation and DNA methylation homeostasis hasbeen explored. Altogether, its 
versatile functions render MBD3 a pivotal part in the epigenetic network. Further, con-
sidering the importance of MBD3 to brain development and cell differentiation, it will be 
of translational value to dissect its implication in human malignant glioma. 
In this chapter, the genome-wide transcription regulated by MBD3 and the possible 
correlation with the survival of glioma patients are examined. In human glioma cells, the 
epigenetic modulation by MBD3 is found to be bidirectional: both active and repressed 
genes are involved. By profiling the transcriptomic changes in GBM cells upon MBD3 
knockdown (MBD3-KD), it is revealed that the differentially expressed genes (DEGs) 
include a myriad of membrane receptors and transcription-related factors. Moreover, sev-
eral novel relations with regard to tumor malignancy and progression are discovered. For 
example, MBD3 is required to facilitate the expression of the major histocompatibility 
complex (MHC) class II molecules, which are proposed to be the key proteins in anti-
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glioma immunity.141-143 Furthermore, depletion of MBD3 enhances transcription from the 
oncogenic miR-17-92 cluster at chromosome 13, to promote the tumor progression. The 
in vitro and in vivo experiments cogently support an anti-proliferative potential of MBD3. 
Last, in an attempt to establish MBD3 as a prognostic biomarker, a clinical cohort of gli-
oma patients has been followed up for 60 months. According to the results, a concurrent 
enrichment of MBD3 and 5hmC in tumor tissue indicates a better progression-free sur-
vival (PFS) and overall survival (OS), which confers promising information for future 
large-scale clinical studies.    
 
4.2 Methods and Materials 
4.2.1 Cell Culture and MBD3 Knockdown 
For the in vitro experiments, human SF767 GBM cells were routinely cu tured in Is-
cove’s Modified Dulbecco’s Medium (IMDM) supplementd with 10% fetal bovine se-
rum, 1% antibiotics, and 1% glutamate. After revival from liquid nitrogen, the cells sub-
cultured for 4 to 6 passages were used for knockdown experiments. Specific siRNAs tar-
geting human MBD3 mRNA and scramble siRNAs were obtained from Santa Cruz Bio-
technology (sc-35867). Transfection was conducted using the recommended siRNA Rea-
gent System (sc-45064). The knockdown effects were d t rmined by qRT-PCR and im-
munofluorescence staining. From the results, a 70-75% of knockdown efficiency can be 
maintained up to 6 days after transfection (Figure 4.2A), based on which microarray, pro-




4.2.2 RNA Microarray and Data Analysis 
The whole-genome difference in transcriptome between low-grade glioma and GBM, 
as well as the DEGs in GBM cells before and after MBD3 knockdown were investigated 
with the SurePrint G3 Human Gene Expression 8 × 60KMicroarray Kit (Design ID: 
028004, Agilent). This array chip covers 27,958 Entrez Gene RNAs and 7,419 long non-
coding RNAs (lncRNAs). Four biological replicates or clinical samples were prepared for 
each group. With RNA extracted by TRIzol reagent (Life technologies, for biopsy tissues) 
or RNeasy Mini Kit (Qiagen, for cultured cells), cDNA and Cy3-labeled cRNA were se-
quentially synthesized with the Agilent LowInput QuickAmp Labeling Kit. The hybridi-
zation step lasted for 17 h at 65°C. After mild wash, the array slides were imaged with a 
SureScan scanner followed by feature extraction. The hybridization quality was assessed 
by monitoring the spike-in signals of ERCC and E1A control probes. Then the raw fluo-
rescence readouts from the array were normalized to the intensity value of the 75th per-
centile of all non-control probes. For genes with multiple probes, the expression was nu-
merically averaged. Approximate 2,000 DEGs based on fold-change and p-value (fold-
change > 3 and p-value < 0.05 for clinical samples; fold-change > 1.5 and p-value < 0.1 
for cultured cells) were determined with moderated t-test in the GeneSpring GX software. 
Protein classification was done with PANTHER (http://www.pantherdb.org).144, 145 GO 
analysis was performed with GeneSpring GX. The DEGs-involved cellular functions and 
diseases were analyzed with the IPA online tool (http://www.ingenuity.com/products/ipa). 
The information of differentially expressed lncRNAs was manually annotated and cross-
verified with referring to: 
EMBL-EBI database (http://www.ebi.ac.uk)  
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lncRNA database (http://lncrnadb.com)  
miRBase (http://www.mirbase.org) 
Human lincRNA catalog (http://www.broadinstitute.org/genome_bio/human_lincrnas)   
The complete microarray raw data have been deposited to NCBI GEO (GSE79878). 
 
4.2.3 Methylation-Specific PCR (MSP) for the CIITA Promoter IV Region 
The methylation status in the promoter IV region of the CIITA gene was determined 
by MSP. After DNA extraction and global methylation a alysis (see detailed protocol in 
Chapter 3.2.6), bisulfite conversion was performed with EZ DNA Methylation-Lightning 
Kit (Zymo Research). The PCR primers and reaction cdition followed the published 
protocol.146 The amplicons from unmethylated primers and methyla ed primers were run 
through 3% agarose gel pre-stained with the GelRed dy  (Biotium). The gel band intensi-
ty was quantified with the ImageJ software (http://imagej.nih.gov/ij). 
 
4.2.4 Construction of Lentivirus and Cell Transduction 
A MBD3 shRNA was designed for the in vivo tumor formation assay. The shRNA (5’ 
– GCAAGATGCTGATGAGCAAGATG – 3’) was constructed into he pLent-U6-GFP-
Puro plasmid. Then the psPAX2 and pMD2.G packaging plasmids were co-transfected 
with the pLent-U6-GFP-Puro/pLent-MBD3 shRNAs in HEK293ft cells for 48 h accord-
ing to manufacturer’s instructions. Medium with virus was collected after 48 h of trans-
fection and concentrated by centrifuge. Titer of viruses was tested and then preserved in -
80°C. Human U87 GBM cells were infected with the shRNA construct for 48 h and se-
lected with puromycin (0.75 mg/mL). 5 × 106 infected cells (GFP/MBD3 shRNAs) were 
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injected to the thalamus of mice (BALB/c-nu, body weight 18-22 g, 1-month old). One 
month after injection, the mice were sacrificed and the tumors were taken out for meas-
urement. 
 
4.2.5 Clinical Samples 
A panel of primary glioma biopsy samples with characterized WHO grade and nor-
mal brain tissues from non-cancer pathologies were obtained from the Department of 
Neurosurgery at Xiangya Hospital of Central South University (Changsha, Hunan, China), 
with informed consent from all involved patients. By matching their clinical properties, 
MBD3 and 5hmC levels, 14 glioma patients were enrolled to the follow-up cohort, and 
their basic information was listed in Table 4.1. All patients received surgical resection to 
the extent feasible, followed by radiation therapy and chemotherapy which were given 
around 2-4 weeks after the first surgical removal. Radiation therapy was given with a 
dose of 1.8 Gy/d and a total dose of 50-56 Gy, including 30-36 Gy for brain and spine, 
plus 20 Gy for the original tumor site as the local boost. Chemotherapy mainly involved 
oral administration of temozolomide. One treatment cycle of chemotherapy was a con-
secutive administration of 150 mg/(m2·d) for 5 days in every 4 weeks. 8 cycles were giv-
en in total. All surgical operations were performed in the Department of Neurosurgery at 
Xiangya Hospital; and the radiation therapy and chemotherapy were administered by the 
Department of Oncology at Xiangya Hospital. For clini al sample preparation, after a 
pathologist confirmed the tumor grade according to the 2007 WHO Classification of Tu-
mors of the Central Nervous System, the tumor DNA and RNA were immediately ex-
tracted from the surgically resected tissues and the rest of the tumor was paraffin embed-
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ded. A 60-month follow-up after surgery was conducted: PFS is defined as the living 
time before tumor recurrence; OS is defined as the tim before clinical death or last fol-
low-up. This study was approved by the Ethic Committee of Xiangya Hospital of Central 
South University. 
Table 4.1 Information of patients enrolled for the clinical follow-up 
Patient # Gender Age Symptoms Tumor Location 
G II_1 Female 37 Seizure L. frontal 
G II_2 Male 36 Headache R. temporal 
G II_3 Female 46 Headache; Visual impairment L. frontal & temporal 
G II_4 Male 42 Seizure; L. limb weakness R. frontal 
G III_1 Male 44 R. limb weakness & numbness L. frontal & parietal 
G III_2 Male 48 Nausea & vomiting L. temporal 
G III_3 Male 62 Visual impairment R. frontal 
G III_4 Male 57 Poor memory; Headache L. insula 
GBM_1 Male 37 Seizure; R. limb weakness & numbness L. frontal & parietal 
GBM_2 Male 58 Headache; Poor memory R. temporal & insula 
GBM_3 Male 27 Headache; Dizziness; Seizure L. temporal 
GBM_4 Male 46 Headache; Visual impairment; Poor memory L. temporal 
GBM_5 Female 55 Headache L. temporal 
GBM_6 Female 26 R. limb weakness R. frontal & parietal 
 
4.2.6 Dot Blot for 5hmC in Clinical Samples 
Genomic DNA from normal brain or tumor tissues was isolated by cell lysis buffer 
(100 mM Tris-HCl, pH = 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 0.667 µg/µL pro-
teinase K) at 55°C overnight. In the second day, the samples were added with an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1 saturated with 10 mM Tris, pH = 
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8.0, 1 mM EDTA), mixed completely, and centrifuged for 5 min at 14,000 g. The aque-
ous layer solution was transferred into a new Eppendorf tube and precipitated with equal 
volume of 100% isopropanol. The genomic DNA was recov red and dissolved with 10 
mM Tris-HCl (pH = 8.0). The DNA samples were further sonicated into 500 bp with a 
Misonix sonicator 3000 system. The concentration of sonicated DNA was determined by 
Nano-Drop 1000 (Thermo Scientific). The sonicated gnomic DNA was denatured in TE 
buffer with 0.4 N NaOH at 100°C for 10 min, immediately chilled on ice for 10 min, and 
spotted onto a positive-charged nylon transfer membrane (GE Healthcare) with a Bio-Dot 
Apparatus (Bio-Rad). The membrane was baked for 30 min at 80°C and then blocked 
with PBS containing 5% dry milk and 0.1% Triton X-100 for 1 h at room temperature. 
Rabbit anti-5hmC antibody (1:10,000, Active Motif) was applied to the membrane and 
incubated at 4°C overnight. In the next day, the membrane was rinsed with fresh PBS and 
the colorimetric signal was developed after incubation with HRP-conjugated secondary 
antibody for 30 min. The final signal was visualized with an ECL-Plus system (Amer-
sham Pharmacia Biotech). 
 
4.2.7 Immunohistochemistry for Tissue Slides 
5 µm-thick tissue slices were sectioned from surgically resected, formalin-fixed par-
affin-embedded tumors and mounted onto polylysine coated slides. Before staining, tis-
sue slides were sequentially deparaffinized and rehydrated using xylene solution and eth-
anol series. Heat-induced epitope retrieval was carried out in boiling Tris-EDTA buffer 
(pH = 9.0) for 20 min, followed by thorough wash with 0.025% Triton X-100 buffer. 
Blocking was conducted in TBS buffer containing 10% goat serum and 1% BSA. The 
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slides were then incubated with 1:200 diluted rabbit anti-MBD3 antibody (Pierce) or 
1:500 diluted rabbit anti-5hmC antibody in a humid 4°C chamber overnight. After sup-
pressing endogenous peroxidase with 0.3% H2O2, goat anti-rabbit IgG-HRP conjugates 
(Life technologies) were applied for 1 h at room teperature. Color signal was developed 
by using AEC staining Kit (Sigma) and then the slides were sealed in mounting medium 
prior to optical imaging. 
 
4.3 Results 
4.3.1 Loss of MBD3 and Relevant Transcriptomic Changes in Gl omagenesis 
A negative correlation between glioma grade and MBD3 expression was noted from 
immunohistochemistry staining (Figure 4.1A-B). Considering that brain is the organ with 
the highest level of 5hmC and it has been postulated s one of the major MBD3-binding 
targets, the amount of 5hmC in the same batch of tumor tissues was thus examined. Evi-
dently, 5hmC displayed a similar reduction pattern in high-grade gliomas (Figure 4.1C). 
Moreover, in high-grade tumors, the intra-group variation of the MBD3 and 5hmC quan-
tities becomes more significant.  
After uncovering the serial loss of MBD3 in the aggravation of glioma grade, the al-
tered gene expression related to MBD3 was profiled by RNA microarray. MBD3 siRNAs 
were introduced into SF767 cells and the knockdown efficiency was confirmed by qRT-
PCR, western blot, and immunofluorescence (Figure 4.2A-B). Next, the genome-wide 
changes in transcriptome were probed by the Agilent microarray (Figure 4.2C). In paral-
lel, the DEGs between low-grade glioma and GBM tissue  were screened for comparison.  
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As shown in Figure 4.3 and Figure 4.4, a considerabl  overlap in the impacted pro-
tein functions between these two sets of DEGs is observed, which implicates that during 
the progression from a low-grade to a high-grade glioma MBD3 is involved in a substan-
tial number of gliomagenetic pathways and functions. For the down-regulated DEGs by 
MBD3-KD, the top-matched gene ontology (GO) is the “MHC II protein complex”, 
which is a surface protein complex presenting antige s to the CD4+ T cells. In analysis of 
the up-regulated DEGs, the major differences between low-grade gliomas and GBM are 
“nucleic acid binding proteins” and “transcription factors”, while depleting MBD3 fur-
ther disturbs the expression of many “receptor proteins” (e.g., G-protein coupled recep-
tors) in GBM cells. Other up-regulated DEGs by MBD3-KD include transport proteins 
(e.g., ion channel proteins and solute carrier family), cyto hrome P450 family, growth 
factors (e.g., FGF and IGF), and dynein proteins, all of which are hallmarks of active cell 
metabolism and proliferation. From another aspect, the MBD3-KD induced DEG-related 
cell functions and diseases, as revealed by the Ingnuity Pathway Analysis (IPA), mainly 
point to “gliomagenesis”, “inflammatory responses”, “metabolism”, “neural signaling” 
and “neurological disorder” in the central nervous sy tem (CNS) (Figure 4.5). Out of the 
7,419 probed lncRNAs, about 600 are determined to be significantly altered upon MBD3-
KD, though the majority of their functions require future exploration due to the lack of a 
well-defined annotation database. One interesting fi ding is that the lncRNAs regulated 
by MBD3 is not fully consistent with the natural distr bution on chromosomes. Instead, a 
skewed distribution is observed. Chromosomes 2, 5, 6 8 13, and X encompass a higher 
percentage of the MBD3-influenced lncRNAs than the expected number. Given the im-
portance of lncRNAs to the chromatin integrity, transcription rate, and post-translational 
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modification, this phenomenon preliminarily suggests that a dysfunction in MBD3 may 
compromise more functions relating to those specific hromosomes. 
 
 
Figure 4.1 Expression pattern of MBD3 in normal brain tissue and malignant glioma. (A) 
Representative IHC images. Images were taken from an Olympus BX53 microscope fit-
ted with a bright illumination and a 20× objective lens. (B) Semi-quantitative results from 
the IHC images using the ImageJ software. (C) Quantity of 5hmC from the same groups 




Figure 4.2 Genome-wide transcriptome regulated by MBD3 in GBM cells. The knock-
down efficiency by the MBD3-siRNA was validated by (A) qRT-PCR (up to 6 days), (B) 
western blot and immunofluorescence staining (at day 4). (C) Upon the knockdown of 






Figure 4.3 Protein classification and GO analysis for the down-regulated genes by 
MBD3-KD. Differences between GBM and low-grade glioma are presented as the refer-
ence (dash line). The number of proteins appearing in both the DEGs is presented in the 
pie chart. The top 5 matched GO terms mediated by MBD3 is presented in table. 
 
 




Figure 4.5 Cellular functions and diseases related to the DEGs in MBD3-KD GBM cells 




4.3.2 Regulatory Function of MBD3 on MHC Class II Molecules 
Since the down-regulation of MHC II protein complex was ranked top in GO analy-
sis, the raw array data for each MHC II subunit were xtracted (Figure 4.6A). MHC class 
II protein complex is a heterodimer comprising α chain and β chain that are transcribed 
from the HLA genes on chromosome 6. Five major HLA-encoding regions exist there: 
HLA-DM, HLA-DO, HLA-DP, HLA-DQ, and HLA-DR. It has been demonstrated that 
MHC class II molecules could be constitutively expressed in glioma cells and their levels 
negatively associate with the tumor invasion and malign ncy.142, 147, 148 As shown in Fig-
ure 4.6B, in comparison with low-grade glioma, GBM has a significantly lower transcrip-
tion of almost every HLA gene. Upon the MBD3 knockdown, ten HLA variants experi-
enced a further decrease. It was speculated that a possible mechanism accounting for this 
MBD3-induced massive down-regulation was through the MHC class II transactivator 
(CIITA) gene since it exhibited the same reduction re d from the array results. The tran-
scription of CIITA is subjected to epigenetic inactiva ion, mainly by DNA methylation in 
its promoter IV region.146, 147, 149 In Chapter 3, MBD3 (by extension the Mi-2/NuRD 
complex) has been demonstrated to maintain a hypomethylated promoter for those genes 
poised to a dynamic transition in expression. Herein, a global DNA hypermethylation 
was noted in MBD3-KD GBM cells, again supporting its demethylation potential (Figure 
4.7A). Using MSP, the methylation level of the CIITA promoter IV region was found to 
rapidly increase by about 20% after 72 hours of MBD3 knockdown (Figure 4.7B), which 
supports an epigenetic control on the CIITA gene by MBD3. Other than DNA methyla-
tion, the extensively dysfunctional lncRNAs on chromosome 6 after depletion of MBD3, 




Figure 4.6 MBD3 facilitates the basal expression of MHC class II molecules in glioma 
cells. The raw signal readings for all the MHC II subunits are presented (left panel). For 
genes having multiple probes in the array, their transcriptional levels were averaged. The 
MBD3-regulated HLA genes in GBM and MBD3-KD GBM cells were compared to that 
in low-grade glioma (right panel). 
 
 
Figure 4.7 MBD3 regulates the expression of the CIITA gene through DNA methylation. 
(A) Global hypomethylation induced by MBD3-KD was asessed by immunoassay (up-
per panel, n = 3) and immunofluorescence (lower panel). (B) Increase in the methylation 
of the CIITA promoter IV region was validated by MSP.   
 
4.3.3 Influence of MBD3 on the Oncogenic miR-17-92 Cluster 
The miR-17-92 cluster is among the first characterized miRNAs underpinning a va-
riety of molecular events to promote oncogenesis. From the polycistronic MIR17HG lo-
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cus, a precursor transcript (pri-miRNA) is transcribed and can yield six mature miRNAs: 
miR-17 (further derive the mature miR-17-5p and passenger miR-17-3p), miR-18a, miR-
19a, miR-20a, miR-19b-1, and miR-92a-1.150 These miRNAs separately or collaborative-
ly regulate a broad spectrum of genes including p21, Rb1, Bim, and Pten, thus controlling 
the cell fate151, 152 (Figure 4.8A, upper panel). Mainly activated by Myc and E2F proteins, 
the increased expression of miR-17-92 has been reported in a number of malignancies.153, 
154 From the microarray results, the number of MIR17HG transcripts in GBM is signifi-
cantly higher than that in low-grade glioma (Figure 4.8A, lower panel). A recent research 
has revealed that MBD3-NuRD was able to directly compete with c-Myc to repress its 
transactivation potential.155 In line with this, the transcriptional level of MIR17HG was 
expected to be further enhanced by MBD3-KD. Afterwards, the quantity of each mature 
miRNA from MIR17HG was determined by qRT-PCR, which proved that the processing 
for the pri-miRNA gave rise to a heterogeneous distribu ion of the final products (Figure 
4.8B, left panel). Specifically, miR-17-3p, miR-18a, miR-19a, and miR-20a experienced 
a substantial increase upon MBD3 knockdown (Figure 4.8B, right panel). As the miR-17-
92 products are closely related to cell proliferation and migration, in vitro and in vivo as-
says were performed to establish the connection between MBD3 and the glioma malig-
nancy (Figure 4.9). Collectively, the obtained results support that a loss in MBD3 would 
release the restraint on Myc and subsequently up-regulate the transcription from the miR-




Figure 4.8 MBD3 fine-tunes the Myc-mediated transcription of MIR17HG. (A) The tran-
scriptional regulation and downstream key targets of MIR17HG are illustrated (upper 
level). The pri-miRNA levels in low-grade glioma, GBM, and MBD3-KD GBM were 
probed by microarray. (B) Composition of the mature miRNAs from MIR17HG in GBM 
and their level changes upon MBD3-KD were quantified by qRT-PCR (mean ± standard 





Figure 4.9 Influence of MBD3 on glioma migration and proliferation. (A) Migration as-
say was performed using GBM cells with and without MBD3-KD. (B) Proliferation rates 
of GBM cells with and without MBD3 siRNA (n = 4, mean ± standard deviation). (C) In
vivo tumor formation assay was performed by injecting GBM cells into mouse brain. By 
H&E staining, the MBD3-KD GBM cells show more pleomrphic and basophilic nuclei 
(scale bars: 50 µm).     
 
4.3.4 Clinical Implication of MBD3 Expression in Glioma Prognosis 
Following the experiments at the molecular and cellular levels, it inspired further ef-
forts to explore the possibility of using MBD3 as a potential prognostic biomarker due to 
its control on the glioma migration and proliferation. To test this hypothesis, a pilot clini-
cal cohort was designed and the enrolled glioma patients were strictly matched with their 
demographic attributes, pathological characteristics, surgical outcomes, and adjuvant 
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therapies. 5hmC has been discovered as the major DNA modification in association with 
MBD3 and early efforts aimed to exploit the clinical implication of 5hmC in glioma have 
been attempted.156-158 The reduction of 5hmC in high-grade glioma was indeed noted in 
this study. It is extensively perceived that epigenetic modifications and their associated 
proteins function in a cooperative manner. Since the DNA modification is not convenient 
to be detected, it is rational to quantitate the rel vant binding proteins as an alternative in 
the clinics. In this regard, a subgroup of 14 patients bearing correlative levels of MBD3 
and 5hmC were recruited. After a 60-month follow-up, MBD3 – as well as 5hmC – ex-
hibited a positive correlation with the patients’ survival. The PFS of GBM patients who 
received gross total resection in surgery and adjuvant therapies (i.e., radiation therapy and 
temozolomide) was considerably proportional to the intra-tumor contents of MBD3 and 
5hmC (Figure 4.10). From the MRI imaging, tumors with a relatively high abundance of 
MBD3 and 5hmC showed a more confined growth whereas a low abundance of MBD3 
and 5hmC was connected to a more aggressive, pre-multifocal growth pattern (Figure 
4.11). The prognostic connection was also perceivable in the enrolled grade II-III patients 
(Figure 4.12). The NCI Rembrandt data further support the positive correlation between 
the expression of MBD3 and the glioma survival, though with a marginal significance of 
difference (p-value = 0.03, Figure 4.13). Altogether, these clinial data establish the po-
tential of MBD3 as a novel epigenetic marker to complement 5hmC in improvement on 




Figure 4.10 Dual-quantification of MBD3 and 5hmC exerts a promising prognostic pow-
er for GBM patients. 6 GBM patients with a correlative abundance of MBD3 and 5hmC 
were followed up after surgery. (A) IHC staining for MBD3 protein and 5hmC. (B) qRT-
PCR for MBD3 mRNA. (C) Dot blot for 5hmC. (D) Survival outcomes of the patients. 




Figure 4.11 Brain MRI images of the GBM patients enrolled in the clinical cohort. Before 
surgery, the tumor growth was examined by the T1 post-c ntrast MRI imaging. The pre-
multifocal growth of MBD3-low GBM features a rapid tumor expansion, aggressive infil-
tration to surrounding normal tissue, and poor survival. In comparison, the spherical, rim-










Figure 4.13 Distinct clinical implications of MBD3 and MBD2 in the survival of glioma. 





Although malignant glioma is a prevalent form of primary brain tumor with devastat-
ing outcomes, research on the involvement of epigenetic mechanisms in gliomagenesis is 
relatively sparse. Like other solid tumors, the progression of glioma is fueled by a pletho-
ra of epigenetic aberrations, while it is yet uncertain whether the reader proteins for DNA 
methylation play a role in this pathology even if some preliminary efforts were attempt-
ed.46, 47 In contrast to other MBD proteins (e.g., MBD1, MBD2, and MeCP2), MBD3 in 
mammalian cells exhibits an elusive and context-dependent interaction with DNA meth-
ylation.159 For example, MBD3 has long been thought to lose its 5mC-binding specificity; 
however, the in vivo co-localization of MBD3 with 5mC and its oxidized derivatives have 
been unambiguously detected in a series of studies.5, 105-107, 117 Furthermore, overexpres-
sion of MBD3 could induce a global DNA demethylation,42 again implying the exquisite 
participation of MBD3 in the DNA methylation homeosta is. Other than being a DNA-
binding protein, MBD3 also serves as a constitutional subunit of the Mi-2/NuRD com-
plex that catalyzes histone deacetylation and nucleosome remodeling.160 MBD3-NuRD 
has proven to be a key factor in inhibition of tumorigenesis and naïve pluripotency in the 
recent reports.155, 161 In spite of some discrepant conclusions, the functio al importance of 
MBD3 to the CNS is evident, from pluripotency to development, from synaptic connec-
tivity to lineage commitment.134, 162-164 Herein this study further uncovered a MBD3-
mediated anti-glioma network. Consistent with the pr vious research, the microarray re-
sults validate that MBD3 exerts an influence on both active and silenced genes in glioma. 
Bioinformatics analysis and the following in vitro/in vivo tests support that a higher level 
of MBD3 might herald a better survival outcome. 
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The MBD3-mediated regulation on MHC class II molecus holds a medical signifi-
cance because it provides us with new avenues to understand the immune escape of glio-
magenesis and to compose targeted immunotherapies. In traditional neuroscience, human 
brain was thought to be an organ with immunological privilege due to the blockade by 
blood-brain barrier (BBB) and the absence of intracranial lymphatic structures,165 which 
can facilitate brain tumors to evade immune surveillance. However, the integrity of BBB 
in glioma is often sabotaged along with the tumor invasion and deficient vasculature, and 
the expression of immunological molecules is found in a variety of glial cells, including 
microglial cells, astrocytes, and even glioma cells. Those discoveries strongly imply an 
anatomic connection between the CNS and immune systm. The recent groundbreaking 
findings of the glioma infiltrating lymphocytes and meningeal lymphatic vessels consoli-
date the participation of immune responses in restricting glioma malignancy.166, 167 En-
hancing the recognition of tumor antigens has therefore been proposed to be a promising 
therapy, and a peptide-based glioma vaccine has been successfully developed to activate 
the MHC class II molecules-dependent CD4+ T cells.143 However, an extensive down-
regulation of MHC class II expression is a pathological characteristic for invading glioma 
cells,142 and thus restoring the expression of MHC class II molecules constitutes the first 
task to the effectiveness of immunotherapy. In the early attempts of anti-glioma immuno-
therapy, in situ delivery of interferon-gamma (IFN-γ) with viral vectors was applied to 
reinforce the expression of MHC class II molecules in glioma cells and enhance the anti-
tumor activity of T cells.168, 169 From this work, the expression of MHC class II molecules 
was confirmed to be utterly low in GBM when compared with that in normal brain tissue 
and low-grade gliomas. Intriguingly, through epigenetically regulating the CIITA gene 
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and relevant lncRNAs on chromosome 6, MBD3 could reactivate the expression of MHC 
class II molecules and may serve as a new therapeutic target to benefit patients from the 
booming immunotherapies. It is anticipated that tumors bearing a high MBD3 abundance 
would respond better to therapeutic vaccination and immune-checkpoint-blockade agents 
(e.g., CTLA-4 and PD-1/PD-1L inhibitors). Furthermore, engineering the MBD3 expres-
sion by novel genome-editing tools also holds a gret promise for future gene therapies.  
Upon recognition of a 6-8 nucleotide “seed” region n target mRNAs to halt transla-
tion or trigger the mRNA degradation, miRNAs pose another layer of post-transcriptional 
regulation in gene expression. A growing body of evid nce has supported the involve-
ment of miRNAs in each stage of oncogenesis. The miR-17-92 cluster, also dubbed “on-
comiR-1”, gives birth to a group of miRNAs that control the cell proliferation, apoptosis, 
and angiogenesis. Activation of the miR-17-92 cluster (i.e., the MIR17HG on C13orf25) 
is mainly driven by two classes of transcription factors – the Myc and E2F proteins. In 
malignant glioma, the copy-number amplification of MIR17HG is rare, indicating its up-
regulation primarily through the overactive Myc or E2F. The loss-of-control on the trans-
activation of miR-17-92 has been identified as a hallmark in hematopoietic malignancies 
and solid tumors. For instance, overexpression of miR-17-92 was reported in neuroblas-
toma and correlated with a poor prognosis.170-172 Other miR-17-92-related cancers in-
clude lymphoma,173 leukemia,174 retinoblastoma,175 medulloblastoma,176 colorectal can-
cer,177 breast cancer178 and so on. In this study, the up-regulation of miR-17-92 in GBM, 
in comparison to low-grade glioma, can be primarily attributed to the significantly higher 
expression of n-Myc (up by 4.46-fold) and E2Fs (e.g., E2F1 up by 7.77-fold and E2F2 up 
by 16.04-fold). In function, MBD3 is able to epigenetically suppress the transactivation 
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potential of Myc proteins. This explains the secondary increase of the MIR17HG tran-
scripts when MBD3 was depleted in GBM cells. 
Encouragingly, MBD3 can complement 5hmC to bring about a remarkable value to 
predict the glioma survival. This positive correlation inspires a mechanistic exploration. 
Catalyzed by the TET family enzymes, 5hmC is the first oxidized derivative of 5mC. The 
content of 5hmC is heterogeneous among different tissues but is most enriched in the 
CNS (0.3-0.7% of the whole genome).179, 180 5hmC locates in the midst of the DNA de-
methylation pathway, hence critical for the dynamic gene activation. Besides being a de-
methylation intermediate, 5hmC has further proven to be a predominantly stable DNA 
modification that regulates a plethora of biological functions through interactions with 
various partners. MBD3 is one of the few identified factors exhibiting appreciable in vivo 
association with 5hmC, though some recent studies failed to validate the specific n vitro 
MBD3-5hmC interaction. Considering the organ-dependent and dynamic nature of epi-
genetic modifications as well as their extensive cooperation in the regulatory network, the 
connection between MBD3 and 5hmC in the CNS ought to be substantive because such 
an enriched cytosine modification (i.e., 5hmC) has to be interpreted by appropriate read-
ers. Interestingly, the enrichment of MBD3 or the 5mC-binding protein MBD2 indicates 
opposite prognosis in the glioma survival even though their sequences are highly similar 
(Figure 4.13). This intra-MBD family divergence higlights the epigenetic intricacy and 
indirectly signifies a MBD3-MBD2 counteraction in the DNA methylation homeostasis 
as discovered in Chapter 3. The clinical implication about 5hmC reduction in a couple of 
cancers, including malignant glioma, has been preliminarily established. This study in-
corporates one of the major 5hmC-associated factors to bolster the reliability of using ep-
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igenetic markers to predict the survival of glioma patients, as well as provides an alterna-
tive epigenetic marker easier to be characterized in clinical samples. In long term, it is 
expected that the obtained information will provide new insights to clinical management 






CHAPTER 5. A PLGA-PEG NANO-DELIVERY SYSTEM FOR EPIGENETIC DNA 
DEMETHYLATING THERAPY 
5.1 Introduction 
Epigenetic aberration has the potential to reshape cellular functions and is apprecia-
bly involved in oncogenic processes. Significantly, epigenetic silencing of tumor sup-
pressor genes is one of the major causes for tumor progression and drug resistance.181, 182 
However, in contrast to genetic mutations, the cancerous epigenetic errors can be re-
versed through chemotherapy with relative ease and less side effects because epigenetic 
modifications do not need to change the DNA sequence of a gene. This feature makes 
epigenetic therapy a promising intervention strategy.183, 184 The essential goal of epigenet-
ic therapy is to target the diseased chromatin in rapidly dividing tumor cells and return it 
to a phenotypic “normal state” while only mildly disturbs the epigenome in healthy cells. 
The most widely studied epigenetic modification in human cancers is DNA methyla-
tion. This modification is one of the prevailing marks for controlling gene expression, 
genomic stability, chromatin integrity, and cell fate.185, 186 Regions with dense CpG dinu-
cleotides, namely CpG islands, are predominantly found at gene promoters and usually 
free of methylation in normal cells. The idea of therapeutically inhibiting DNA methyla-
tion emerged from studies showing that a plethora of genes (mainly tumor suppressor 
genes and apoptosis-related genes) boast a gain-of-methylation (hypermethylation) dur-
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ing tumorigenesis.187, 188 This process is associated with an epigenetic inactivation of the 
gene expression and thus loss of the protein functio s, which leads to the revival of inter-
est in drugs discovered decades ago being potent inhibitors of DNA methyltransferases 
(DNMTs) to restore relevant anti-tumor activities in malignant cells.57, 189 
Two commercially available agents targeting DNA methylation – AZA and DAC – 
are now alternative options for treatment of myelodysplastic syndrome.190, 191 As cytidine 
analogues, AZA and DAC exert their effect by incorporating into replicating DNA and 
inhibiting DNMTs by forming covalent adducts in fast-dividing cells. With more DNMTs 
entrapped, DNA methylation is incrementally reduced along cell proliferation. Eventually, 
demethylation at tumor suppressor genes is achieved in daughter cancer cells, but only 
minimally affects resting or non-dividing cells.192 
A growing body of evidence (from preclinical tests and clinical trials) suggests that 
the DNA demethylating drugs might induce an anti-cancer response in solid tumors.193-196 
However, extending the therapeutic effects of DNA demethylating agents to in vivo solid 
tumors still faces substantial hurdles due to the difficulties in drug delivery and cellular 
uptake.189 In order to attenuate abnormalities of DNA methylation in cancer cells, several 
aspects of the current drug formulation need to be car fully improved: aqueous stability, 
in vivo bioavailability, transmembrane efficiency, resistance to efflux, side effects, and 
long-term efficacy.197 Among the challenges, effective delivery of the DNA demethylat-
ing drugs is perhaps the most significant barrier for expanding the therapeutic indications 
from blood malignancies to solid tumors. 
Efficient accumulation of cytidine analogues in cells relies on the presence of partic-
ular membrane nucleoside transport proteins such as t e hCNT proteins.198-200 The ATP-
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dependent cellular internalization and short half-life of the DNA demethylating drugs in 
physiological liquids would compromise the expected therapeutic activities against solid 
tumors. AZA and DAC are subjected to a series of physicochemical attacks when admin-
istered to human body, mainly including degradation by hydrolysis, deformation of the 
triazine ring, and anomerization of the ribose ring u der neutral-to-basic conditions.201, 202  
One strategy to overcome the pharmacological challenges in drug delivery is to mod-
ify the drug structures. However, a considerable number of those modifications could in-
evitably diminish the therapeutic efficacy and cause nwanted toxicity. A variety of AZA 
derivatives have been developed, yet with decreased performance compared to the paren-
tal drug. Just to name a few here: 5-fluoro-2'-deoxycytidine is highly toxic;203, 204 1-(β-D-
ribofuranosyl)-1,2-dihydropyrimidin-2-one is less potent;205 5,6-dihydro-5-azacytidine 
has a poor incorporation ability;206, 207 2'-deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-
azacytidine (NPEOC-DAC) severely impacts liver function;208 and some drugs require 
pre-activation by certain enzymes: CP-4200 by plasma membrane lipases,209 S110 by cel-
lular phosphodiesterases,210 and NPEOC-DAC by carboxylesterase.207, 208 
Another strategy is to compose a nanoscale delivery system that has the potential to 
improve the therapeutic efficacy of demethylating drugs. An ideal delivery vector should 
protect drugs from premature hydrolysis in blood circulation, increase bioavailability, and 
enhance cellular internalization. With controlled fabrication, nano-carriers could facilitate 
the in situ retention of demethylating agents, extend the exposure of cancerous tissue to 
an efficacious drug concentration, and minimize the re-methylation of tumor-suppressor 
genes until an irreversible elimination of tumor cells. In this regard, the nanomaterial-
protected drug molecules become more effective than parental compounds in treating sol-
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id tumors.211, 212 Till today only a handful of nano-vectors have been d veloped to deliver 
epigenetic chemo-payloads to solid tumors, but none of the past work has demonstrated 
the potential of a poly(lactic-co-glycolic acid) (PLGA)-based system for delivery of the 
DNA demethylating drugs.  
Use of the biodegradable PLGA as the drug delivery system has been well defined, 
while most of the applications were demonstrated to physically encapsulate the drug mol-
ecules. However, this formulation is sensitive to various environmental factors that could 
result in an undesired burst release.213, 214 Instead, chemical conjugation of a drug with 
the backbone of PLGA would greatly enhance the drug stability and also facilitate a pH-
dependent release. Hence, in this work the aliphatic polyester PLGA is combined with 
the hydrophilic polyethylene glycol (PEG) to produce an A-B type of di-block copolymer 
for conjugation with AZA or DAC (Figure 5.1). Under an equimolar drug concentration, 
the nano-conjugate form of drug experiences a rapid endocytosis and can better reactivate 
the apoptotic pathway to inhibit cell proliferation. I  light of this improved cell uptake, a 
low concentration of DAC-PLGA-PEG was applied to sensitize the alkylation-resistant 
glioblastoma cells to temozolomide. These polymers are able to diffuse through loosely 
packed endothelial cell junctions of blood capillares in the vicinity of tumor tissue and 
enrich in tumor cells due to the “enhanced permeation and retention” (EPR) effect. With 
prolonged circulation and bioavailability, AZA-PLGA-PEG gains a more potent i  vivo 
efficacy over free AZA in treating xenografted breast cancers. Notably, the active glycol-
ysis in cancer cells often generates an acidic microenvironment in which the PLGA-PEG-
based nano-vector could release the conjugated drug molecules at a faster rate than in 
normal cells. This unique property substantially avoids an excessive damage to normal 
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cells. Taken together, this chapter describes a novel delivery strategy for DNA demethyl-
ating agents and provides a cost-effective formula for future pharmaceutical applications.  
 
 
Figure 5.1 Design of the nano-conjugate and principle of delivery. 
 
5.2  Methods and Materials 
5.2.1 Synthesis of PLGA-PEG-OCH3 (Conjugate 1) 
The PLGA-PEG di-block was synthesized as described in previous studies with mi-
nor modifications.215 PLGA 50:50 with an average molecular weight 8,586 Da (0.31 mM) 
was dissolved in dry dichloromethane (DCM, 10 mL). The carboxylic acid group in 
PLGA was first activated by N,N'-dicyclohexylcarbodiimide (DCC, 0.375 mM) and N-
hydroxysuccinimide (NHS, 0.62 mM) at room temperature overnight. The side product 
dicyclohexylurea (DCU) was filtered out; the obtained PLGA-NHS was precipitated by 
ice cold diethyl ether (Et2O) and dried under vacuum. The activated PLGA (2 g) was then 
added into methoxy polyethylene glycol (H2N-PEG-OCH3) (molecular weight = 750 Da, 
0.42 mM) solution in 10 mL dry DCM, and the reaction mixture was stirred at room tem-
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perature for 24 h. The PLGA-PEG conjugate was preciitated out from the reaction mix-
ture by adding Et2O and centrifuged at 3,220 g for 10 min. The supernatant was discarded 
and the polymer was washed with a mixture of Et2O and hexane 50:50 (3 × 5 mL) to re-
move excess reagents. Finally, the polymer was dried under vacuum for 24 h to obtain 
the conjugated product (yield = 92.83%). The coupling efficiency was determined by 1H 
NMR spectroscopy: ~99.2% of PLGA was conjugated with PEG. 
 
5.2.2 Activation of PLGA-PEG-OCH3 by Succinic Anhydride (Conjugate 2) 
The PLGA block of Conjugate 1 was modified by reacting with succinic anhydride 
to produce HOOC-PLGA-PEG. 1.78 g of Conjugate 1 wasdis olved in dry DCM (10 mL) 
containing 4-dimethylaminopyridine (DMAP 25% w/v) as  catalyst, and succinic anhy-
dride (39.3 mg) was added. After stirring at 50°C overnight, the DCM was removed in 
vacuum. This Conjugate 2 was re-dissolve in dry DCM and precipitated in ice cold Et2O, 
dialyzed against water for 4 h using MWCO 3,500 andlyophilized (yield = 81%). The 
polymer was characterized by 1H NMR (400 MHz): δ (ppm) = 5.36–5.00 (m, PLGA-
CH2-), 4.94–4.57 (m, PLGA-CH2-), 3.67–3.58 (m, PEG-CH2-), 3.38 (s, PEG-OCH3), 
1.52 (s, PLGA-CH3). The percentage of modification was determined to be 97.2%. 
 
5.2.3 Synthesis of AZA/DAC-PLGA-PEG (Conjugate 3) 
Conjugate 2 (0.08 mM) was dissolved in dry DCM contai ing 4-(dimethylamino) 
pyridinium-4-toluene sulfonate (DPTS, 0.23 mM) and cooled at 0°C. For the reaction 
mixture, AZA or DAC (0.09 mM) dissolved in dry N,N-dimethylformamide (DMF) was 
added with continuous stirring. Then 0.23 mM DCC in pyridine was added slowly to the 
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solution and the reaction was carried out at 4°C for 72 h under N2. The progress of reac-
tion was monitored by TLC with CHCl3/CH3OH (1:4, v/v) as eluent (product retention 
factor: RfAZA = 0.56, RfDAC = 0.68). The DCM and pyridine were removed under reduced 
pressure and the product was re-dissolved in DCM and precipitated in ice cold Et2O. Un-
treated drug and other impurities were removed followed by dialysis. The dialyzed solu-
tion was precipitated in ice cold Et2O/hexane (50:50) mixture, freeze-dried and kept at -
20°C. The drug conjugate was characterized by UV and 1H NMR spectroscopy. 1H NMR 
of AZA-PLGA-PEG (400 MHz): δ (ppm) = 8.56 (s, 1H, H-6), 7.49-4.53 (bs, 2H, NH2), 
5.76 (s, SA-O-CH2), 5.65-5.64 (d, 1H, H-1̍, J = 4), 5.40-5.41 (bs, 1H, OH-2ˈ), 5.25-5.14 
(m, PLGA-CH2-),5.03-4.99 (m, 2H, H-4̍ and OH-3̍), 4.91-4.83 (m, PLGA-CH2-), 3.99 
(m, 1H, H-3̍), 3.84-3.81 (m, 1H, H-2̍), 3.67–3.59 (m, 2H, H-5ˈ; H-5ˈˈ), 3.49 (m, PEG-
CH2-), 3.22 (s, PEG-OCH3), 1.46 (s, PLGA-CH3). 
1H NMR of DAC-PLGA-PEG (400 
MHz): δ (ppm) = 8.56 (s, 1H, H-6), 7.52-7.49 (s, 2H, NH2), 6.15 (t, 1H), 5.26 (s, SA-O-
CH2), 5.25 (m, PLGA-CH2-), 4.91-4.83 (m, PLGA-CH2-), 4.2 (s, 1H, H), 3.76 (1H, H), 
3.6–3.7 (m, 1H, H), 3.7–3.5 (m, 2H, H), 3.49 (m, PEG-CH2-), 3.22 (s, PEG-OCH3), 1.46 
(s, PLGA-CH3). The coupling efficiency revealed that over 90% of the carboxyl ends of 
PLGA were conjugated with AZA.  
 
5.2.4 Synthesis of PLGA-PEG-FITC (Conjugate 4) 
The di-block polymer PLGA-PEG-NH2 (600 mg) was prepared as discussed above 
and dissolved in 20 mL DCM. FITC (22.3 mg) was dissolved in 250 µL of a mixture of 
DCM/pyridine and added to the copolymer solution. The reaction was stirred at 4˚C for 
24 h in dark. The resultant conjugate was precipitated by ice cold Et2O (125 mL). The 
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polymer was centrifuged at 3,220 g for 30 min. The supernatant was discarded and the 
polymer was washed thoroughly by Et2O (5 mL × 3) and dried under vacuum overnight. 
The yield of FITC conjugation was determined using fluorescence spectrometry at an ex-
citation wavelength of 485 and emission at 530 nm. 
 
5.2.5 Preparation and Characterization of Nano-Micelles 
Due to the amphipathic property of PLGA-PEG, it would form nano-micelles in so-
lution and the drug molecules are protected in the core. Non-fluorescent (only drug-
containing conjugate) and fluorescent (drug-containing conjugate : FITC-containing con-
jugate = 2 : 1) nano-micelles were prepared by filmdispersion method.216, 217 A proper 
amount of compounds was dissolved in chloroform at room temperature. The solvent was 
then removed under reduced pressure to form a dry polymer film. This film was hydrated 
with 10 mM HEPES buffer (pH = 7.4) at room temperatu e for 30 min. The nano-
micelles were extruded through a 200 nm polycarbonate membrane. The yield of prod-
ucts was determined by UV-Vis spectroscope for non-fluorescent nano-micelles and fluo-
rimeter for fluorescent nano-micelles. 
During synthesis, gel permeation chromatography (GPC) was performed to monitor 
each conjugation using an Agilent 1200 series Wyatt D wn Heleos-II system equipped 
with a UV, LSD & RID detector. DMF was used as the mobile phase at a flow rate of 0.3 
mL/min through OHpak SB-803 HQ column [8.0 × 300 (mm): inner diameter × length] 
at 40°C. GPC calibration was constructed using polystyrene standards. The size and mor-
phology of nano-micelles were determined by transmis ion electron microscope (TEM, 
Philips, CM1000) with the acceleration voltage of 100 kV. Samples were diluted to 0.5 
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mg/mL with HEPES buffer and stained with 0.8% uranyl acetate. The surface charge of 
nano-micelles was measured with a ZetaPlus analyzer (Brookhaven). 
 
5.2.6 Uptake and Release Assays 
The uptake and intracellular release of fluorescent na o-micelles were characterized 
by confocal imaging, FCS, PCH, and FLIM. The pH-dependent drug release kinetics was 
evaluated with a UV-Vis method. AZA/DAC-PLGA-PEG nano-conjugate was suspended 
in 500 µL PBS (pH = 5 or 7.4) and dialyzed (MWCO 3,000 Da) against 1.5 mL medium. 
Then the tubes were placed in an orbital shaker setting at 120 rpm and 37°C. At prede-
termined time points (1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h), a 10 µL aliquot was withdrawn 
and replaced with fresh buffer. The released AZA or DAC concentration was quantified 
at a characteristic wavelength: AZA – λmax 254 nm (pH 5) and 223 nm (pH 7.4); DAC – 
λmax 244 nm (pH 5) and 220 nm (pH 7.4).
218 The calibration curve for drug quantity was 
linear over the concentration range from 100 to 4000 ng/mL. 
 
5.2.7 In vitro Therapeutic Tests of DAC-PLGA-PEG against Glioblastoma 
Human SF767 and U87 GBM cells were cultured in IMDM medium supplemented 
with 10% fetal bovine serum, 1% antibiotics, and 1%glutamate. MTT assay was used to 
test the short-term cell viability after DAC-PLGA-PEG and temozolomide treatment. In a 
96-well plate, 3,000 cells were seeded in each well to grow for 24 h, followed by incuba-
tion with appropriate drugs. After 72 h, the culture medium was quickly removed and the 
cells were rinsed with clean 1 × PBS. The cells were then incubated with 100 mL fresh 
medium containing 10 mL thiazolyl blue tetrazolium bromide solution (MTT, 5 mg/mL 
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in PBS as stock) for 3-4 h and the formed formazan w s dissolved with 150 mL acidic 
isopropanol prior to measurement by a microplate reader at the absorbance of 570 nm. 
For long-term proliferation assay, 5,000 cells were se ded to a T25 flask at day 0, and the 
cell number under each specific condition was recorded for 8 days. During the long-term 
treatment, the global DNA methylation was quantified with colorimetric immunoassay at 
day 4 and day 8, respectively. In addition, four apoptosis-related genes (p53, p21, Caspa-
se3, and BRCA1 by qRT-PCR) and cell cycle progression (flow cytometry) were evalu-
ated upon different treatments.  

















5.2.8 In vivo Therapeutic Tests of AZA-PLGA-PEG against Breast Cancer 
After testing the in vitro cytotoxicity of AZA-PLGA-PEG by MTT assay, the in vivo 
anti-tumor potential was assessed. Female nude mice (18-25 g in body weight) were sub-
cutaneously implanted with 5 × 106 MCF7 cells. Following xenografting, tumors were 
allowed to grow for another 21 days until reached 190-200 mm3. Mice were sorted ran-
domly into three groups: control, free AZA treatment, and AZA-PLGA-PEG treatment. A 
total of 16 doses of PBS saline, free AZA (1 mg/kg), or AZA-PLGA-PEG conjugate 
(with equivalent AZA content of 1 mg/kg, micelle concentration = 1.53 mg/mL) were 
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administered via intraperitoneal (IP) injection to each group in four weeks (two cycles of 
eight consecutive doses). Tumor volume was measured twice a week with an electronic 
caliper (v = 0.5 × L × W2 mm3) and the body weight of mice was monitored in parallel. 
All animal handling followed the guidelines of the Purdue Animal Care and Use Com-
mittee and approved by the Purdue Center for Cancer Research. 
 
5.2.9 Statistical Analysis 
In significance test: Student’s t-test (two-tail) was used for two sample comparison, 
and ANOVA was used for multiple sample comparison. All the analyses were performed 
with the OriginPro software. Without specific note, all data are presented with mean and 
standard deviation. 
 
5.3 Results and Discussion 
5.3.1 Synthesis and Characterization 
Cytidine analogues are highly unstable in aqueous cndition, which greatly restricts 
their experimental and clinical applicability. This instability is due to the rapid hydrolysis 
and opening of the heterocyclic nitrogen ring caused by nucleophilic attacks at the N-5 
position. The formed N-(formylamidino)-N-β d-ribofuranosylurea intermediate would be 
then slowly converted into 1-β d-ribofuranosyl-3-guanylurea.202 This destructive decom-
position hinders efficient drug conjugation and storage. New experimental methodologies 
are thus needed for more effective particle formulation and drug delivery. 
Two methods have been developed for incorporation of drug into nano-vectors. The 
most widely used is physical entrapment, which is quite simple as no chemical modifica-
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tion is required. However, burst release is a grand shortcoming due to a premature loss of 
the physically loaded drug before reaching the target site. The second method is chemical 
conjugation in which the drug molecules are covalently bonded to nano-vectors and then 
undergo a controlled release since additional mechanisms are usually needed to trigger 
the pharmacological action. This strategy has not been widely adopted mainly because of 
the limited number of reactive sites available on a nano-vector and few conjugation reac-
tions that would not impact the raw compounds. For instance, even a tiny chemical linker 
could drastically change the structure and therapeutic value of a chemotherapeutic drug.  
In this study the drug-containing nano-conjugate was prepared with a three-step syn-
thetic route (Figure 5.2A). First, NHS-activated PLGA reacted with PEG to form the co-
polymer PLGA-PEG. Then the terminal hydroxyl group of PLGA-PEG was converted to 
carboxylic group by reaction with succinic acid, and the succinylated PLGA-PEG copol-
ymer was allowed to react with the 5’-OH of AZA or DAC in the presence of DCC and 
DPTS, to result in the formation of AZA/DAC-PLGA-PEG conjugate. Products were iso-
lated and purified by precipitation and dialysis, followed by characterization with GPC 
(Figure 5.2B), TEM (Figure 5.2C), and 1H NMR (illustration with AZA-PLGA-PEG in 
Figures 5.3-5.5). The drug content was determined to be 25 µg/mg for AZA-PLGA-PEG 
and 22.9 µg/mg for DAC-PLGA-PEG. The formed nano-micelles in solution are spheri-
cal in shape with an average size of about 50 nm. The surface charge was found to be 
nearly neutral by zeta-potential (Table 5.2). The pysicochemical characteristics of pol-
ymeric nanoparticles including size, shape, and surface charge are critical factors for their 
stability, in vivo pharmacokinetics and bioavailability. In human body, exogenous mole-
cules have to evade the reticuloendothelial system (RES) which can otherwise opsonize 
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the “invader molecules” and subsequently induce a dgradation or phagocytosis by mac-
rophages.219 PLGA-nanoparticles below 100 nm with a hydrophilic surface modification 
such as PEG can  minimize opsonization and clearance by the RES, which would prolong 
the circulation time and allow more drug delivered to tumor lesions.220 Another rationale 
for PEGylation aims to solve the problem that positive-charged particles easily bind to a 
variety of cells in the body, such as vascular endothelial cells, before reaching the target 
loci. Hence, it is favorable to maintain a nano-vector as either neutral or slightly anionic 
for stabilization and preventing non-specific drug loss.221, 222 
 
 
Figure 5.2 Synthesis of AZA/DAC-PLGA-PEG nano-conjugate. (A) Steps for chemical 
conjugation. (B) Successful conjugation for each comp nent was validated by decreased 

















Figure 5.5 1H NMR spectra and the corresponding peak assignments for AZA-PLGA-
PEG. 
 
Table 5.2 Basic characteristics of the nano-micelles with different compositions   
Nano-micelle Composition Particle Size (nm) Surface Charge (mV) 
AZA-PLGA-PEG 45 ± 5.2 -0.87 ± 2.1 
DAC-PLGA-PEG 55 ± 6.4 -0.99 ± 1.5 
PLGA-PEG-FITC 59 ± 3.4 -1.10 ± 2.3 
 
5.3.2 Uptake and Release Kinetics 
To track the drug uptake and release kinetics, fluorescent nano-micelles were incu-
bated with cells for up to 6 hours. From the time-lapse confocal imaging, it can be seen 
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that the cross-membrane diffusion rapidly completed within 2 hours (Figure 5.6A). Next, 
a more quantitative exploration with single-molecule fluorescence tools was performed 
(Figure 5.6B). By mixing 50 nM drug-containing conjugate and 25 nM FITC-containing 
conjugate, the original concentration of the nano-micelle solution was determined to be 
13.8 nM in FCS calculation. The intracellular concetration of nano-micelles could reach 
83.5 ± 5.0 nM within the first hour of incubation, validating the high uptake efficiency of 
this PLGA-PEG-based nano-vector. After 4 hours, the intracellular concentration peaked 
at 145.8 ± 13.4 nM as shown in Figure 5.6B. Notably, the diffusion coefficient of nano-
micelles in living cells did not experience drastic changes within the detection window 
(Figure 5.6B, inset), which indicates that no significant aggregation or abrupt particle dis-
integration occurred in 6 hours. From PCH, the averg  brightness of nano-micelles dis-
played a gradual increase (Figure 5.6C). It gives rise to a speculation that some PLGA-
PEG fragments with FITC tags hydrolyzed from early taken nano-micelles would inte-
grate into newly internalized micelles due to physical adsorption or hydrophobic force. In 
the fluorescence images, a uniform distribution of nano-micelles over the entire cell was 
noted without a significant compartmental entrapment, implying an endo-lysosomal elu-
sion (Figure 5.6D). The results from FCS and PCH together suggest that the maximum 
uptake of the PLGA-PEG nano-micelles could occur within 1 hour (Figure 5.6C, black 




Figure 5.6 Uptake and distribution of PLGA-PEG nano-micelles. (A) Confocal imaging 
of cells incubated with fluorescent nano-micelles. (B) Autocorrelation functions from live 
cells were fitted with a 3D diffusion model to obtain the diffusion coefficient (inset) and 
concentration of internalized nano-micelles. (C) Summary of the average concentration 
and brightness of nano-micelles in cancer cells (n > 20 cells, mean + S.E.M.). (D) Escape 
of nano-micelles from the endo-lysosomal system. 
 
To verify the pH-dependent PLGA hydrolysis, n vitro drug release assay was per-
formed in acidic and neutral environments. As shown in Figure 5.7B, the hydrolysis rate 
was significantly faster at an acidic pH than in a eutral environment. Approximately 85% 
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of the conjugated drug was released at pH 5.0 within the first 12 hours, whereas only ~40% 
was released at pH 7.4. This supports the susceptibility of the ester bond-based PLGA-
PEG conjugate to acid; however, a more comprehensiv investigation is required for fu-
ture in vivo applications due to the lack of analytical methods to distinguish the intact 
AZA/DAC from the degraded intermediates.192, 223 Moreover, the hydrolysable chemical 
links within the conjugate render the rate of drug elease a near zero-order kinetics under 
physiological pH, which provides additional benefits or in vivo usage. 
 
 
Figure 5.7 pH-dependent drug release from PLGA-PEG nano-micelles. (A) UV-Vis spec-
tra of cytidine analogue and the PLGA-PEG copolymer below 300 nm. (B) In vitro drug 
release kinetics in acidic or neutral environment (n = 3).   
 
In cancer cells with a relative acidity caused by the Warburg effect, upon the hydrol-
ysis of PLGA a fast accumulation of lactic acid and glycolic acid was expected, and these 
two products would further acidify the intracellular environment to facilitate a drug re-
lease cascade. To some extent, the acidifying pH could not only advance the PLGA hy-
drolysis but also slow down the triazine ring-opening decomposition of the drugs,218 thus 
conferring a better efficacy against cancer cells. Since a reduced fluorescence lifetime of 
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FITC is a sensitive measure of low pH, FLIM was used to assess the PLGA hydrolysis-
related acidification in living cells. Figure 5.8A shows the time-course FLIM images at 
different incubation times. It is evident to see that along the incubation the fluorescence 
lifetime of FITC was continuously shortening, which an also be perceived from the shift 
in the lifetime histograms (Figure 5.8B). Taken together, the intracellular behavioral 
mode for PLGA-PEG nano-micelles was proposed (Figure 5.9). Having a size of 50-60 
nm, the formed nano-micelles can rapidly enrich in ca cer cells within 1-2 hours and the 
delivery of AZA/DAC here, to a great extent, is thus independent of nucleoside trans-
porters. Instead, the trend of an initial linear increase and a later saturation stage as re-
vealed by FCS, strongly suggest that the cell internalization of sub-100 nm PLGA-PEG 
nanoparticles is the outcome of a cooperation between fluid-phase pinocytosis and clath-
rin-mediated endocytosis,224 in contrast to the mechanism for large-sized nanoprticles 
(e.g., via extracellular release of the drug payload to contacting cells).225 The rapid endo-
lysosomal escape is another advantage for the PLGA-PEG based delivery since a further 
anionic-to-cationic reversal of the surface charge facilitates the nanoparticle to interact 
with the endo-lysosomal membrane and achieve the escap  in 10 minutes.226 Afterwards, 
the internalized nano-micelles begin to be hydrolyzed and are sensitive to acidic pH in 




Figure 5.8 PLGA hydrolysis-induced acidification inside cells. (A) FLIM images collect-
ed from the FITC channel. (B) Lifetime histograms of the internalized FITC at different 
time points.  
 
  
Figure 5.9 Single-molecule behavior of PLGA-PEG-based nano-micelles in cancer cells. 
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5.3.3 DAC-PLGA-PEG Sensitizes Glioblastoma Cells to Temozol mide 
Arising from normal glial cells, glioblastoma (GBM) constitutes the most prevalent 
primary brain tumor in adults. Even with gross total resection in surgery and adjuvant 
therapy, the median survival for GBM patients is only 14.6 months and the two-year sur-
vival is approximately 30%. As the frontline chemotherapy for GBM, temozolomide is 
able to elicit a radical anti-tumor effect via inducing alkylation at the guanine residues in 
DNA. However, after a temporary remission GBM would virulently relapse and become 
chemo-resistant due to its infiltrating growth and rapid evolution to overcome selection 
pressure. It has been recently demonstrated that pretreating the chemo-resistant GBM 
cells with DAC could considerably sensitize GBM cells to temozolomide.227 In light of 
this finding, it will be of tremendous value to improve the pharmacodynamics of DAC to 
further its application in GBM.   
First, two GBM cell lines with distinct responses to temozolomide were confirmed 
by MTT assay. Cells were treated with temozolomide at a concentration of up to 30 µM 
for 72 hours. From the results, U87 cells exhibited full response to temozolomide treat-
ment and a dosage of 30 µM could suppress the cell proliferation by 90% (IC50 was es-
timated to be ~20 µM). In contrast, SF767 cells did not show any significant response to 
30 µM temozolomide (Figure 5.10A). In the subsequent experiments testing combination 
therapy, SF767 cells were first sensitized with DAC or DAC-PLGA-PEG with equivalent 
drug content (50 nM) for 24 hours, followed by treament with 30 µM temozolomide for 
another 48 hours. When given separately, both DAC and DAC-PLGA-PEG showed cer-
tain cytotoxicity because of the non-specific effect, but the nano-conjugate form of drug 
was more effective than the free drug due to the improved delivery efficiency. For cells 
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pretreated with DAC or DAC-PLGA-PEG, 30 µM temozolomide could successfully sup-
press the proliferation rate by 47% and 62%, respectively (Figure 5.10B). This set of ex-




Figure 5.10 Therapeutic potential of combination trea ments against GBM cells. (A) Dis-
tinct responses to temozolomide in U87 and SF767 cells. (B) Synergistic effects between 
temozolomide and DAC or DAC-PLGA-PEG were tested in SF767 cells (n = 6).  
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A critical pitfall for conventional PLGA-based delivery comes from its premature 
burst release.228, 229 To solve this problem, the design of this study opted to chemically 
conjugate DAC to the PLGA backbone instead of physically load the drug. This formula-
tion merits a sustainable and controlled release. Hence, a better long-term efficacy from a 
combinatorial therapy was expected. As presented in Figure 5.11A, the proliferation rate 
of SF767 cells under a combination treatment using DAC-PLGA-PEG and temozolomide 
is significantly lower (by ~70%) than that with DAC and temozolomide in 8 days. It was 
also noted that a larger extent of DNA demethylation c uld be achieved by DAC-PLGA-




Figure 5.11 Long-term effects of the combination therapy. (A) The proliferation profiles 
of SF767 cells under combination treatments (n = 3). (B  The global changes in DNA 
methylation were monitored during the whole process (n = 3). 
 
Since both DAC and temozolomide function by alkylating DNA yet on different nu-
cleotides, the next query is to test whether their synergistic effect stems from triggering a 
more intense response to DNA damages. Quantitative RT-PCR was thus applied to check 
four key genes relating to DNA damage and apoptosis: p53, p21, Caspase3, and BRCA1. 
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Consistent with the cytotoxicity assays, 30 µM temozol mide alone did not evoke any 
significant changes in the transcription of these genes in SF767 cells, whereas the combi-
nation treatment (DAC-PLGA-PEG and temozolomide) radic lly reactivated p53 and p21 
(Figure 5.12A). On the contrary, Caspase3 and BRCA1 were not influenced, verifying a 
DAC-induced, Caspase-independent apoptosis and the impaired BRCA1 function in gli-
oma cells.230, 231 The elevation of p53 and p21 could in turn halt the cell cycle progression 
at the checkpoints. Examined by flow cytometry, a much larger proportion of cells were 
found to be arrested in the G2/M-boundary when the combination treatment was adminis-
tered (Figure 5.12B), which is in agreement with the previous research on DAC pharma-
cology.232, 233 Collectively, these data suggest that one major mechanism for DAC to po-
tentiate temozolomide in GBM cells hinges on better eliciting the DNA damage-induced 
proliferation retardation, though it cannot rule out that the observed increase in p53 and 





Figure 5.12 DAC-PLGA-PEG nano-conjugate better sensitize  the chemo-resistant GBM 
cells to temozolomide. (A) Transcriptional levels of f ur DNA damage-responsive genes 
were quantified by qRT-PCR after 72 hours of treatment (n = 4). (B) Cell cycle progres-
sion was evaluated by flow cytometry. 
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5.3.4 AZA-PLGA-PEG Enables Better Targeting Efficiency against Breast Cancer in 
Mouse Model 
Similar to DAC-PLGA-PEG, AZA-PLGA-PEG showed a significantly improved cy-
totoxicity over free AZA in treating MCF7 breast can er cells (Figure 5.13). As men-
tioned above, the primary obstacles in utilizing DNA demethylating agents to treat solid 
tumors are the in vivo instability and rapid body clearance. To assess the bioavailability 
of AZA-PLGA-PEG after circulation through the RES, peritoneal membrane, hepatic 
portal system, and renal exclusion system, subcutaneously xenografted tumors with 
MCF7 cells were established in mice. Eight doses of 1 mg/kg AZA-containing solution 
were IP injected every two weeks when the body weight of mice was closely monitored 
(Figure 5.14A). After four weeks’ treatment, free AZ  showed minimal anti-tumor effect 
whereas AZA-PLGA-PEG could constrain the tumor growth in a time-dependent manner 
(Figure 5.14B). This in vivo experiment clearly demonstrates the superior bioavail bility 
of AZA-PLGA-PEG. Future study could be undertaken to optimize dosage regimens and 






Figure 5.13 Therapeutic effects using free AZA and AZA-PLGA-PEG nano-conjugate 





Figure 5.14 In vivo anti-tumor activity of AZA-PLGA-PEG with improved rug stability 
and bioavailability. (A) The body weight of mice was monitored to control severe side 
effects. (B) The volume of xenografted tumors was reco ded during the four-week treat-
ment (n = 5). 
 
5.4 Conclusion 
This study aims to address a major problem with regard to drug delivery that has a 
promising significance to popularize epigenetic therapies. To reach this goal, a nano-
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delivery system utilizing PLGA-PEG copolymer was developed and characterized. Upon 
stabilizing the cytidine analogue drugs by conjugation, the formed nano-micelles feature 
superior drug solubility, uptake efficiency, pH-dependent release, in vivo bioavailability, 
and anti-proliferative potential. This work constitu es one of the very first to chemically 
link the drug molecules to the PLGA backbone instead of physical encapsulation, there-
fore preventing unwanted burst release. By single-molecule fluorescence experiments the 
rapid internalization and hydrolysis processes in an acidic cancer cell were quantitatively 
monitored. In the proof-of-concept, DAC-PLGA-PEG was shown to potently sensitize 
the chemo-resistant GBM cells to temozolomide by reactivation of the p53-p21 pathway. 
AZA-PLGA-PEG achieved better in vivo efficacy targeting breast cancer xenografts in 
comparison to free drug. Collectively, these results demonstrate the effectiveness of DNA 
demethylating drugs in treating solid tumors when an appropriate delivery strategy is de-





CHAPTER 6. OPTOGENETIC TOOLS FOR EPIGENOME EDITING WITH SPATI-
OTEMPORAL PRECISION 
6.1 Introduction 
From the ENCODE and Roadmap Epigenomics projects, a huge number of epigenet-
ic marks are statistically associated with specific phenotypes and diseases.97, 234 However, 
in order to decode epigenetic language to mechanistic understanding in biology, tools 
able to control loci-specific epigenetic states are ne ded. With respect to technical devel-
opment, the ability to adjust epigenetic modification is also essential for drug screening, 
disease modeling, epigenetic therapy, and developmental research. The first wave of 
technical breakthrough came from the invention of agents that can globally change DNA 
methylation and histone acetylation. Owing to those u ful tools, our knowledge of envi-
ronment-gene interaction, transcriptional regulation, phenotypic diversity, and cancer ini-
tiation has been elevated to a higher level. Moreover, some of the developments such as 
cytidine analogues and histone deacetylase inhibitors have shown promising applications 
in clinical medicine. Nevertheless, a grand challenge stagnating the first generation of 
tools for epigenome editing is the limited spatiotemporal accuracy in that the majority of 
singleplex causations could hardly be researched. In the last decade, loci-specific epige-
nome editing has been made possible thanks to the discovery of programmable DNA-
binding molecules including ZFPs, TALEs, and CRISPR/Cas9 (detailed description in
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Chapter 1.2.4).235 These advances have sparked an explosion of revolution in biotechnol-
ogy and single-cell engineering. By customizing a DNA-binding motif with an epigenetic 
modifier, sequence-specific addition or removal of an epigenetic mark can be achieved in 
individual cells.74, 75, 77, 80, 236, 237 From this moment, the methodologies for single-cell 
manipulation are entering an era of nanoscale precision. On the basis of current tech-
niques, this chapter aims to improve another aspect in loci-specific epigenome editing – 
the temporal precision. By incorporating light-sensitive proteins into the epigenome edit-
ing machinery, the timing and extent of epigenetic modulation could be fine-tuned with a 
standard light source, noninvasively.  
The discoveries of the light-sensitive (optogenetic) proteins in plant and microbial 
origin offer ample opportunities to manipulate the dynamic nature of gene expression 
with spatiotemporal precision. CRY2-CIB1 and PHYB-PIF6 are representative optoge-
netic protein pairs and their heterodimerization cabe activated by blue light and red 
light, respectively.238, 239 Upon illumination by 390-480 nm light, CRY2 is photoactivated 
to couple with CIB1 whereas the PHYB-PIF6 coupling s dependent on a 650-670 nm 
illumination. Further, these light-inducible associations are reversible: CRY2-CIB1 will 
automatically dissociate in the absence of light whilst PHYB-PIF6 needs an additional 
infrared illumination (~750 nm) to detach.240, 241 The importance of optogenetic interac-
tion was first recognized as in relation to flowering and circadian rhythms of plants.242, 243 
Recently, genetically engineered molecular constructs containing CRY2-CIB1 or PHYB-
PIF6 have been used as novel means for subcellular loc lization and (epi)genome-editing 
in a variety of contexts.81, 244-249 Yet, limited techniques are available to precisely quantify 
an optogenetic reaction. Herein this present study demonstrates the feasibility of dynamic 
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monitoring the interaction kinetics of CRY2-CIB1 and PHYB-PIF6 with single-molecule 
fluorescence tools. Moreover, by constructing a pair of DNMT3A-CRY2-mCherry and 
TRF1-CIB1-EGFP fusion proteins, this chapter provides the proof-of-concept for selec-
tive de novo DNA methylation at subtelomeric CpGs with tunable acquisition and tem-
poral precision.  
 
6.2 Methods and Materials 
6.2.1 Preparation of Optogenetic Proteins 
Plasmids encoding the optogenetic protein pairs were obtained from the Addgene 
global plasmid repository (http://www.addgene.org/): pCRY2PHR(498 aa)-mCherryN1 
(#26866), pCIB1(335 aa)-pmGFP (#28240), pCIBN(the N-terminal 170 aa from CIB1)-
pmGFP (#26867), pAL149 [pCMV-PHYB(1-908)-10aaLinker-mCherry-Kras4BCT 
(#22275)], pAL175 [pSV40-mYFP-PIF6APB (#22276)]. Plasmids were transformed into 
the stellar competent cells (PT-5056-2, Clontech) for amplification and selection. Extrac-
tion and purification of plasmid DNA was performed with QIAprep Spin Miniprep Kit 
(Qiagen). The blue and red light-induced optogenetic associations were demonstrated in 
HeLa cells transfected with proper protein pairs. For in vitro kinetics experiments, trans-
fected cells were lysed by M-PER mammalian protein extraction reagent (Pierce), fol-
lowed by acetone precipitation to remove lipid content. The concentration of fluorescent 
optogenetic proteins in cell lysate was determined by FCS. The phycocyanobilin (PCB) 
required for PHYB-PIF6 dimerization was extracted by methanolysis from Spirulina ly-
sate. 5 µM PCB was added to the reaction buffer or cell culture medium when testing the 
PHYB-PIF6 interaction.  
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6.2.2 FCS for Measuring the CRY2-CIB1/N Binding Kinetics 
A single blue laser-based FCS was used for measuring the in vitro CRY2-CIB1/N 
binding kinetics. One prominent advantage of this approach is that the 465 nm picosec-
ond pulsed excitation for GFP is also the peak wavelength to induce the CRY2-CIB1/N 
dimerization. As the size of CRY2 is significantly larger than CIB1/N, the diffusion rate 
of a free CIB1/N is much faster than that of a CRY2-CIB1/N complex. Hence, the two-
component 3D diffusion model can be used to characte ize the free and bound forms of 
CIB1/N-GFP in a quantitative manner. Figure 6.1A outlines the experiment design: a 20-
30 µL of the sample droplet containing equimolar concentrations of CRY2-mCherry and 
CIB1/N-GFP proteins is mounted to a humid microscopi  chamber from which a time-
course fluorescence fluctuation trace is recorded. Along the blue laser excitation, mono-
dispersed CRY2-mCherry and CIB1/N-GFP are expected to couple with each other. Due 
to the high numeric aperture of the applied objectiv  lens (focal length = 0.25 mm), the 
excitation beam waist would rapidly expand below and bove the focal plane so that the 
majority of optogenetic proteins in the droplet can be efficiently photoactivated. Then the 
obtained fluorescence fluctuation trace is segmented to several time windows and an au-
tocorrelation function is generated from each interval. By fitting with the diffusion model 
algorithm, the proportion of free and bound CIB1/N-GFP molecules at a specific time 




Figure 6.1 Scheme for measuring the CRY2-CIB binding kinetics by FCS. (A) The exci-
tation profile for a sample droplet containing optogenetic proteins. A single blue laser is 
used to excite GFP and in the meantime to induce the optogenetic association. (B) The 
two-component 3D diffusion model is used to characterize the free and bound CIB mole-
cules. 
 
6.2.3 PIE-FLCS for Measuring the PHYB-PIF6 Binding Kinetics 
In order to monitor the real-time PHYB-PIF6 binding kinetics, two illumination 
sources were implemented. Here pulsed interleaved excitation-based fluorescence life-
time correlation spectroscopy (PIE-FLCS) was used to reduce photodamage and better 
separate the single-molecule information of PIF6-YFP ( igure 6.2A). In PIE mode, the 
red (for dimerization induction) and blue light pulses (for YFP excitation) are intermitted 
by a 5 ns delay and the laser repetition rate is set to 40 MHz. Therefore, the peak energy 
imposed on the sample is half of that under a synchronized excitation. Moreover, the red 
laser-caused autofluorescence and background noises would radically decay in that 5 ns 
gap period, which benefits a high signal-to-noise ratio (SNR) when collecting the YFP 




Figure 6.2 Scheme for measuring the PHYB-PIF binding ki etics by PIE-FLCS. (A) The 
excitation profile for a sample droplet containing optogenetic proteins. The blue laser is 
for fluorescence detection and the red laser is for optogenetic induction. The PIE mode 




Figure 6.3 Changes in the diffusion rate and fluorescence lifetime of PIF6-YFP due to its 
association with PHYB-mCherry. 
 
During the PHYB-PIF6 coupling, two events occurring to PIF6-YFP can be used to 
reflect the dimerization rate. First, the FCS diffusion curve of PIF6-YFP would shift from 
a one-component mode to a two-component mode (Figure 6.3A). Second, the TCSPC 
decay of PIF6-YFP would become steeper due to the FRET between YFP and mCherry 
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(Figure 6.3B). Combining these two sets of information, quantities of the free and bound 
PIF6-YFP can be precisely calculated.   
 
6.2.4 Molecular Cloning of DNMT3A-CRY2-mCherry and TRF1-CIB1-EGFP 
To demonstrate the loci-specific epigenome editing with optogenetic tools, two new 
fusion proteins were constructed by molecular cloning. CRY2-mCherry and CIB1-EGFP 
were fused to DNMT3A and TRF1, respectively. The coding sequences of DNMT3A 
(#35521, Addgene), CRY2-mCherry, EGFP (#23027, Addgene), CIB1, and TRF1 
(#16058, Addgene) were PCR amplified from individual templates and assembled to the 
C-terminus of pHTN HaloTag CMV-neo Vector (Promega).   
Sequence information: 































































6.2.5 Illumination for Selective Subtelomeric de novo DNA Methylation 
In order to illuminate large populations of transfected cells for the downstream bisul-
fite-pyrosequencing, a mounted high-power LED with a peak wavelength of 455 nm and 
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a DC2100 LED driver (Thorlabs) were applied. The illumination beam size was adjusted 
to uniformly cover the surface area of culture vessels. After optimization, the illumination 
power in all subsequent experiments was determined to be 1-2 mW/cm2. 
The methylation state at the representative subtelom ric CpGs (selected from chro-
mosomes 7q, 8q, 16p, 18p, 21q, and Xp) was quantified with bisulfite-pyrosequencing. 
Extracted from treated cells, 600 ng genomic DNA was bisulfite converted with EZ DNA 
Methylation Kit (Zymo Research) and then PCR-amplified against predetermined regions 
using PyroMark PCR Kit (Qiagen). The PCR products were subjected to pyrosequencing 
in a PyroMark Q24 system.  
Table 6.1 Primers used for bisulfite-PCR. 5’-/5BiosG/ is the 5’-biotinylation tag on the 
primers for subsequent pyrosequencing 
 Forward Reverse Prod.
7q AGTGGATATTTAGGTTTATGATTGTAAT 5’-/BiosG/ CTCCCCAAAAAACACTTTACTCTTTCACA 257 
8q TGTTTTTTTTTTTTTATTAAAAGGTGAGTT 5’-/BiosG/ AAAAATCTCCAAAAAACCCTTATAAAC 139 
16q GTTTTAATTGGTTTTTGATTTTGATTAT 5’-/BiosG/ CTCAACACAAACCTAAAAATCACC 164 
18q 5’-/BiosG/ GTTGTGGTGTAGGTTTATAATTT ACCCCCAAAAAAAAACTACAAAAACC 185 
21q TTTTGGAGGATTGTGTTTAGATAGATAT 5’-/5BiosG/ CCCAACTCCTTCCAAATAAAT 137 
Xp GTGGGTTAGTTTGTATTGAGGTAGGTAT 5’-/5BiosG/ AAAACCCCCTAACCCCTCC 307 
 
Table 6.2 Information of the sequenced regions and the sequencing primers. Y/R is the 
potential methylated cytosine positions at the target CpGs 














21q TTYGTAGGTGTGYGYGGYGTTYGTAAGTGGTTAGTATAAYGTYGGGYGAA GTTTAGATAGATATTGGTTTTTTTA 





6.3 Results and Discussion 
6.3.1 Demonstration of Optogenetic Association in Living Cells 
First, the CRY2-CIB1 and PHYB-PIF6 mediated subcellular redistribution of tagged 
proteins was demonstrated in living HeLa cells. Thedesign principle was to localize one 
part of the optogenetic pair at a specific cell compartment and then attract the comple-
mentary part to the same compartment with proper illum nation. As shown in Figure 
6.4A, TRF1-CIB1-EGFP predominantly locates in cell nucleus due to the presence of 
TRF1 whereas CRY2-mCherry primarily distributes in cytoplasm. After 30 min illumina-
tion with blue light, CRY2-mCherry could be efficiently imported to nucleus because of 
the optogenetic CRY2-CIB1 dimerization. In another d monstration, PHYB-mCherry is 
pre-anchored to cell membrane by incorporating a Krs CAAX-motif to its sequence 
while PIF6-YFP freely diffuses inside cells. After a short red illumination, PIF6-YFP ex-
periences radical redistribution to cell membrane, validating the PHYB-PIF6 coupling 
(Figure 6.4B). By comparing the YFP fluorescence in cytoplasm and on membrane, a re-
version in relative intensity can be clearly seen after illumination. In consistence, the in-
tracellular concentration of PIF6-YFP is reduced from 600 nM to 320 nM in a sampling 
region. Furthermore, FLIM-FRET confirms the specific PHYB-PIF6 dimerization on cell 
membrane as only an inter-protein distance below 10 nm can induce the non-radiative 
energy transfer between YFP and mCherry (Figure 6.4C). Taken together, these experi-
ments prove the effectiveness of optogenetic proteins as powerful tools to translocate bi-




Figure 6.4 Optogenetic associations in living HeLa cells. (A) TRF1-CIB1-EGFP recruits 
cytoplasmic CRY2-mCherry to nucleus after blue illumination. (B) Membrane-anchored 
PHYB-mCherry induces redistribution of PIF6-YFP after red illumination. FCS quantita-
tively confirms the reduction of PIF6-YFP in cytoplasm. (C) FLIM-FRET confirms the 
specific association between PHYB-mCherry and PIF6-Y P on cell membrane. 
 
6.3.2 In vitro CRY2-CIB1/N Binding Kinetics 
Initially, fluorescence cross-correlation spectroscopy (FCCS) was proposed to be a 
fitted technique to probe the CRY2-CIB1/N binding kinetics since they were separately 
labeled with different fluorescence proteins. However, it was reported that the activity of 
cryptochrome could be impacted by green irradiation o some extent. A green-to-yellow 
excitation would suppress the equilibrium of flavin redox critical for CRY2 activation 
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and thus retard its optogenetic association with CIB1.250, 251 To avoid this possible nega-
tive effect, a single blue laser-based FCS was applied. 
In a 20 µL reaction droplet containing 1 nM CRY2-mCherry and CIB1/N-GFP, fluo-
rescence fluctuation was recorded for 300 s and one autocorrelation function was gener-
ated from each 50 s time window. In Figure 6.5, a right-shift of the autocorrelation func-
tions was observed for both combinations, indicating more bound proteins being formed 
along the illumination. By fitting with two-componet 3D diffusion model, the free and 
bound protein components were determined. Compared to CIB1-GFP, CIBN-GFP pos-
sesses a faster diffusion rate (i.e., a larger diffusion coefficient) due to its smaller size 
(Figure 6.6A): 59.77 ± 6.11 µm2/s versus 44.11 ± 4.13 µm2/s in free form, and 2.59 ± 
0.62 µm2/s versus 2.19 ± 0.53 µm2/s in bound form. According to a recent study, CYR2 
per se would be self-clustering under blue illumination in addition to dimerizing with 
CIB1,252, 253 which explains why the observed changes in diffusion coefficient from free 
to bound CIB1/N do not support a 1:1 binding stoichiometry with CRY2. However, the 
fast mobility of CIBN was found not to increase its coupling efficiency with CRY2 in 
vitro (Figure 6.6B). During the 300 s detection window, CIB1 yielded about 15% more 
bound component than CIBN. This phenomenon implies that a less active diffusion is 
conducive to stabilize the CRY2-CIB1 dimerization and the C-terminal 165 amino acids 
in CIB1 may be required to facilitate the association kinetics. Furthermore, the excitation 
power-dependent optogenetic association was observed (Figure 6.6B, inset). Overall, this 
study provides the first quantitative evidence showing that CIB1 is better than CIBN as 




Figure 6.5 In vitro association kinetics of CIB1-CRY2 and CIBN-CRY2 probed by FCS.  
 
  
Figure 6.6 Characterization of the CRY2-CIB association rate. (A) Diffusion coefficients 
of free and bound CIB1/N-GFP (n = 9, mean + S.E.M.). (B  The incremental percentage 
of bound CIB1/N-GFP in a 300 s detection window (n = 5). 
 
6.3.3 In vitro PHYB-PIF6 Binding Kinetics 
As perceived from the preliminary cell experiments, the PHYB-PIF6 dimerization 
occurs much faster than CRY2-CIB1. Therefore, in this part, fluorescence lifetime was 
included in analysis to better characterize the freand bound PIF6-YFP. A 50 µL reac-
tion droplet containing 100 nM PHYB-mCherry and PIF6-YFP was mounted for PIE il-
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lumination. Two methods were used to determine the percentage of free/bound PIF6-YFP 
at a specific time point. In the TCSPC method, the bound form of PIF6-YFP is distin-
guished from the free form based on the occurrence of FRET. According to the law of 
fluorescence decay: 0( ) expi
i i
t
I t I a c
τ
 
= − + 
 
∑ , the sum TCSPC histogram can be de-
composed to three components: the bound (FRET) component, the free (non-FRET) 
component, and the background (Figure 6.7A). By integrating the photon counts under 
each component, the percentage of bound proteins can be calculated at a resolution of 1 s 
(Figure 6.7B). In the second method, more sensitive FLCS is used to precisely determine 
the concentration of free/bound PIF6-YFP. The differential decay patterns of FRET and 
non-FRET PIF6-YFP make it possible to generate a TCSP  filter function to weigh the 
possibility of a detected single photon from which component (Figure 6.8A). With this 
filter function, a fluorescence lifetime-dependent au ocorrelation function can be extract-
ed by FLCS. Hence, featuring a steady fluorescence lifetime, photons from non-FRET 
PIF6-YFP are separated. Autocorrelation functions are established from each 5 s time 
window and the concentration information of free PIF6-YFP is obtained (Figure 6.8B). 
These two methods have their own advantages and in the meantime complement each 
other: the TCSPC decomposition provides a delicate temporal resolution and FLCS bring 




Figure 6.7 TCSPC method for measuring the PHYB-PIF6 binding kinetics. (A) Mathe-
matical decomposition of the sum TCSPC. (B) The association rate of PHYB-PIF6 is cal-
culated by reassigning the photon counts to each lifetime component (n = 5). 
 
 
Figure 6.8 FLCS method for determining the concentration of free PIF6-YFP. (A) Based 
on differential fluorescence lifetimes a filter function is generated to extract photons from 
the free component. (B) The concentration of free PIF6-YFP is determined by fitting the 
FLCS autocorrelation functions at each time point. 
 
When comparing the CRY2-CIB1 and PHYB-PIF6 binding kinetics, PHYB-PIF6 
exhibits a much more efficient association. For 50% of proteins to get optogenetically 
coupled, CRY2-CIB1 takes ~250 s whereas PHYB-PIF6 only needs ~5 s, which awaits 
future research to investigate the underlying mechanisms. One possible explanation could 
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be related to their functions in plants. Plants heavily rely on these two classes of optoge-
netic proteins to sense the blue and red wavelengths from sunlight. Considering the fact 
that blue light has a higher energy than red light, op ogenetic proteins responding to the 
red wavelength might have evolved to gain a better photosensitivity. However, the addi-
tional demand for PCB impedes an extensive utilizaton of the PHYB-PIF6 pair in bio-
logical engineering.  
 
6.3.4 Optogenetic Induction of Subtelomeric de novo DNA Methylation 
Next, two constructs expressing TRF1-CIB1-EGFP and DNMT3A-CRY2-mCherry 
were introduced to HeLa cells for demonstration of a light-inducible, loci-specific epige-
nome editing. TRF1-CIB1-EGFP serves as the targetin component to localize the enzy-
matic reaction of DNMT3A-CRY2-mCherry at subtelomeric regions (Figure 6.9A). Up-
on transient expression, TRF1-CIB1-EGFP shows a punctate distribution in cell nucleus, 
highlighting the telomere positions (Figure 6.9B). From FCS measurements, two distinct 
components were detected: a fast-diffusing free form (D = 5.96 ± 0.58 µm2/s) and a slow-
diffusing bound form (D = 0.92 ± 0.08 µm2/s). A remarkably high percentage of bound 
form of TRF1-CIB1-EGFP was noted inside those punctate spots (83 ± 17%). In contrast, 
Nuc-GFP molecules predominantly exist as a free-diffusing form in whole nucleus (D = 
11.23 ± 2.06 µm2/s). To further confirm the binding specificity of TRF1-CIB1-EGFP to 
telomeric regions, a co-immunofluorescence staining for endogenous TRF2 proteins was 
performed and the co-localization between TRF1-CIB1-EGFP and TRF2-Alexa647 was 
unambiguously observed (Figure 6.9C). These results pport that the constructed TRF1-
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CIB1-EGFP successfully recognizes the characteristic TTAGGG repeats in telomeric and 
subtelomeric regions.254   
Then the blue light-induced association of TRF1-CIB1-EGFP and DNMT3A-CRY2-
mCherry was assessed by FLIM-FRET. In control cells, the average fluorescence time of 
EGFP was determined to be 2.41 ns (Figure 6.10A). On the other hand, the average fluo-
rescence lifetime of EGFP in co-transfected cells wa  continuously decreased under blue 
illumination. A 15% reduction in the EGFP fluorescen  lifetime was achieved in 5 min 
at an energy level of 8 mW/cm2 (Figure 6.10B). This significantly shortened fluorescence 
lifetime is attributed to the FRET effect between EGFP and mCherry in the optogenetic 
pair. In the following optimization, the association rate was found to be tunable by the 
light intensity, for instance, an energy level of 1 mW/cm2 giving rise to a similar FRET 
response in about 10 min. These data were validated wi h Co-IP experiments using EGFP 
antibody and western blot using DNMT3A antibody. From the illuminated cell lysate, 
DNMT3A-CRY2-mCherry could be co-immunoprecipitated by EGFP antibody (data not 
shown). Collectively, this set of experiments proves the formation of TRF1-CIB1-EGFP 
and DNMT3A-CRY2-mCherry complex at the desired loci after blue light illumination.   
After the blue light-mediated re-localization of DNMT3A-CRY2-mCherry to chro-
mosomal ends, the de novo methylase activity of DNMT3A is expected to increas  the 
DNA methylation levels at subtelomeric CpGs since no CpGs exist in telomeric regions 
(Figure 6.11A). Six subtelomeric regions containing a number of CpGs were selected for 
bisulfite-pyrosequencing after varied illumination durations. The pyrosequencing results 
corroborate the blue light-induced increase in methyla ion at most of the CpGs. In general, 
a longer light exposure results in more de novo methylation (Figure 6.11B). For example, 
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with 4 h illumination the following changes occur: 12% increase at the 2nd CpG site of 
Chr. 7, 7% increase at the 1st CpG site of Chr. 8q, 9% increase at the 1st CpG site of Chr. 
16p, 19% increase at the 2nd CpG site of Chr. 18p, 5% increase at the 8th CpG site of Chr. 
21q, and 12% increase at the 3rd CpG site of Chr. Xp. This substantial de novo methyla-
tion fully demonstrates the efficacy of optogenetic tools even in a short time. The differ-
ential increases for each CpG position could be ascribed to their different starting meth-
ylation levels and varying distance to the nearest TTAGGG repeat.255, 256 Admittedly, 
some slight non-specific de novo methylation was noted (i.e., an increase in methylation 
with 0 h illumination) due to the catalytic action f DNMT3A. However, in a selected 
centromeric control region, no additional increase in methylation was observed upon cell 
exposure to blue light. Hence, this line of research demonstrates the feasibility of loci-




Figure 6.9 Localization of TRF1-CIB1-EGFP to telomeric and subtelomeric regions. (A) 
Design of the fusion protein. (B) The distribution a d diffusion characteristics of TRF1-





Figure 6.10 Blue light-induced re-localization of DNMT3A-CRY2-mCherry to telomeric 
regions. (A) FLIM measurement for HeLa cells transfected with TRF1-CIB1-EGFP. (B) 
FLIM measurement for cells co-transfected with TRF1-CIB1-EGFP and DNMT3A-





Figure 6.11 Blue light-induced e novo DNA methylation at the subtelomeric CpGs. (A) 
Scheme of the working mechanism for optogenetic induction. (B) Analysis of changes in 
DNA methylation at the selected CpG positions of six chromosomes. 
 
6.4 Conclusion 
Optogenetic protein pairs are emerging as a group of powerful tools in single-cell bi-
oengineering. However, for a better implementation of these photosensitive molecules, 
quantitative information regarding their associations is needed. In this chapter for the first 
time the real-time binding kinetics of CRY2-CIB and PHYB-PIF, the major optogenetic 
pairs responding to blue and red lights, is adequately characterized. By adapting single-
molecule fluorescence techniques including FCS, FLIM-FRET, TCSPC, and PIE-FLCS, 
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optogenetic associations can be quantified with a subsecond resolution. Furthermore, this 
study contributes to the pioneering efforts aimed to realize an on-demand, loci-specific 
epigenome editing. By constructing DNA-targeting and epigenetic-effecting proteins that 
can be photoactivated to function in predetermined sites, de novo DNA methylation was 
successfully achieved at subtelomeric CpGs. Hence this work provides a novel, noninva-
sive method to manipulate epigenetic state and offers a unique avenue for epigenetic re-
search. In addition, the diversity of the available optogenetic tools makes it possible to 
multiplexing epigenome editing. Last but not least, in vivo application of optogenetic 
tools is anticipated if advanced illumination facilities such as endoscopic multi-photon 





CHAPTER 7. CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
During the historical transition from the superstitious astrology and alchemy to the 
modern physics and chemistry, quantitative detection and utilization of mechanical forces, 
electricity, light, chemical structures, and reaction kinetics have resulted in revolutionary 
advances. Today, in order to decipher the epigenetic code in a single cell at the single-
molecule level, nanoscale measurements and engineering of various biomolecules and 
activities hold the key. In conventional molecular biology, methods like electrophoresis, 
PCR, and immunoassays heavily rely on ensemble results estimated from a population of 
cells, thus overlooking the cellular heterogeneity and dynamic intermediates. In light of 
advanced optical tools and nanotechnology, scrutinizing the epigenetic network with high 
spatiotemporal resolutions is made possible and provides us with new dimensions to in-
terpret life and diseases. 
Metazoan species, especially human being, contains billions of variedly differentiat-
ed cells playing the fundamental roles in every biological process. For cells within the 
same tissue or organ, at a given time point they might have distinct morphological traits 
and functional states that are substantially dictated by epigenetic modulations. Single-cell 
and single-molecule techniques offer us tremendous opportunities to inspect subcellular 
components with unparalleled sensitivity and specificity. Advanced optics and nanoscale 
engineering are particularly advantageous in characte izing the epigenetic conservation
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and variations implicated in dynamic biological systems. Moreover, the fast evolving and 
enriching nanobiotechnology will not only benefit the basic research but also hold great 
promise in healthcare practices. 
 
 
Figure 7.1 Content composition of this dissertation. 
 
My dissertation work aims to dissect the DNA methylation-related molecules and 
events at the nanoscale using single-molecule detection techniques and nano-engineering 
approaches (Figure 7.1). My research theme can be summarized to two major aspects: 
characterization and manipulation. With regard to analytical characterization, my study 
takes a unique route to quantitatively examine DNA methylation, i.e., via monitoring the 
154 
 
DNA methylation-associated proteins. In Chapter 2, for the first time the dynamic pro-
cess of active DNA demethylation is successfully correlated with the millisecond-level 
mobility of MBD3, providing a novel strategy to inspect the global hypomethylation in 
cancer. In Chapter 3, single-molecule fluorescence tools are further employed to explore 
the binding preference, real-time association, and stoichiometric transition of MBD3 in a 
single cell cycle, which constitutes a pioneering effort to analyze the intricacy of DNA 
methylation homeostasis in single living cells. The results of my study reveal a crucial 
role of MBD3 in the inheritance of DNA methylation. I spired by these new findings, in 
Chapter 4 I have conducted a translational study to delineate the regulatory network by 
MBD3 in human malignant glioma and established it as a possible prognostic biomarker. 
With exciting discoveries accumulated, I am fully convinced that single-cell and single-
molecule techniques unleash the power for us to better assess epigenetic mechanisms in a 
micron-sized human cell, therefore complementing the future wave of precision medicine. 
The other focus of my dissertation lies in controlling DNA methylation with nanoscale 
accuracy and tunability. In Chapter 5, a novel PLGA-PEG-based di-block polymeric 
nano-vector is developed to deliver the DNA demethylation drugs, and this formulation 
features significant improvements on the aqueous stability, in vivo bioavailability, cell 
uptake efficiency, pH-dependent release, and anti-prol ferative potential. Other than the 
global reshaping with DNA demethylation agents, in Chapter 6 the loci-specific epige-
nome editing using optogenetic proteins is demonstrated. Compared to the first genera-
tion of epigenome-editing methodologies, the tools developed herein add another layer of 
modulation: i.e., the epigenetic status of a specific region can be adjusted on demand with 
high temporal controllability. Taken together, this di sertation delivers a comprehensive 
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toolbox for epigenetic research involving DNA methylation and unearths a number of 
intracellular phenomena inaccessible by traditional means. 
Admittedly, a variety of properties with respect to single-cell probing and single-
molecule engineering need further optimization. First, to achieve high-throughput readout 
from most single-molecule techniques is a grand challenge since the trade-off between 
the detection speed and precision limits the number of assessed targets at a time. Incorpo-
ration of the single-molecule analysis to the workflow of flow cytometry could be a pos-
sible solution. Second, so far even though numerous single-cell datasets have been ob-
tained, a large proportion of them were from in vitro or ex vivo conditions. It is more im-
perative to interpret the behaviors of a single cell within its in vivo context. More efforts 
for whole-body implementation of the newly developed tools such as fluorescence fluc-
tuation spectroscopy, fluorescence lifetime imaging, single-photon counting, optogenetics, 
and epigenome editing remain to be invested. Third, fully nontoxic and biocompatible 
nanomaterials are still scarce at present. Therefore, utilization of synthetic biomaterials 
including peptide nanosensors, xeno-nucleic acids, and DNA origami might be the future 
options. Last but not least, to correlate the micros ale genotype with the macroscale phe-
notype in epigenetics requires a combinatorial elucidation of the central dogma in biology. 
With the advent of single-cell sequencing techniques, the hope of obtaining quantitative 
information of DNA and RNA from a trace amount of cells is becoming a reality. Hence, 
further research in understanding the epigenetic inricacy and its regulatory impact in a 
loci-specific manner can be expected. 
The biggest challenge begets the best work. Single-cel  and single-molecule studies 
are not commonplace in biomedicine yet but only a fraction of the possibilities, if any 
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have been explored. Opportunities abound in enhancing our knowledge of embryogenesis, 
development, aging, metabolic disorders, degenerativ  diseases, and cancer – the solution 
to all our unsolved questions exclusively hinges upon the extent we know about and ma-
nipulate the function of a single cell, in which millions of actions occur in the timescale 
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